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ABSTRACT 
MECHANISTIC STUDIES OF PROTEIN LIPIDATION: YEAST 
PALMITOYLTRANSFERASE AKR1P AND PROTEIN 
FARNESYLTRANSFERASE 
by 
Xiaomu Guan 
 Chair: Carol A. Fierke  
Protein palmitoylation is a widespread lipid modification in which cysteine 
thiols on a substrate protein are modified with a palmitoyl group. Mutations in 
palmitoyltransferases responsible for this modification are associated with a 
number of neurological diseases and cancer progression. Defining the active 
site and catalytic mechanism of palmitoyltransferases represents a key step 
towards understanding its biological significance. Akr1p, one of the first 
identified protein palmitoyltransferases, is an 86 kDa yeast integral membrane 
protein. Mutagenesis studies of Akr1p suggest that a conserved DHYC motif 
serves as a potential active site; the hypothesized mechanism is a two-step 
mechanism where the palmitoyl group is transferred from palmitoyl-CoA to 
Akr1p, and finally from Akr1p to the substrate protein. A covalent intermediate 
has been detected using radioactive assays. In this study, we elucidated the
xi 
 
role of each amino acid in the DHYC motif using mutagenesis. In addition, 
mutagenesis of all of the cysteine residues in Akr1p along with mass 
spectrometric analysis demonstrated that the DHYC cysteine is the site in 
Akr1p where a covalent thioester intermediate forms. Based on these data, we 
propose a detailed mechanism for palmitoylation catalyzed by Akr1p, which 
may shed light on the mechanism of other palmitoyltransferases within the 
DHHC protein family. 
Protein farnesylation is another important lipid modification in which the 
cysteine of a substrate protein is modified by attachment of a 15-carbon 
farnesyl group which results in membrane localization of the protein. Protein 
farnesyltransferase (FTase) catalyzes farnesylation of a specific C-terminal 
“Ca1a2X” sequence of substrate proteins. Here we analyze the determinants of 
recognition of the a2 residue by FTase, demonstrating that completely 
conserved tryptophan residues in FTase, although not essential for maintaining 
the farnesylation activity, play an important role in modulating the substrate 
selectivity of FTase. Mutagenesis studies demonstrate that the conserved 
W102β and W106β residues modulate both the reactivity of FTase and 
substrate selectivity based on the size of the binding pocket. The complete 
conservation of these two amino acids suggests that maintenance of the exact 
substrate selectivity of FTase is crucial for the in vivo activity.
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CHAPTER I 
INTRODUCTION 
General Introduction of Protein Lipidation 
    As many as 25-40% of eukaryotic cellular proteins are estimated to be  
membrane-associated proteins (1). To interact with the hydrophobic lipid 
bilayer environment of cell membranes, proteins require hydrophobic surfaces 
formed by structures such as α-helices or β-sheets. In addition to that, 
permanent cotranslational additions or posttranslational modifications under 
dynamic enzymatic control also allow proteins to be attached to the membrane 
by lipid anchors, which serve as the hydrophobic interface to interact with the 
hydrocarbon core of the lipid bilayer. These lipid modifications are increasingly 
recognized as important mechanisms for membrane targeting and subcellular 
protein trafficking which allow proteins to obtain a variety of functions. To date 
hundreds of proteins have been shown to be covalently modified with lipid 
groups, many of which are important for the cellular function of these proteins. 
For example, the lipidated forms of receptors, monomeric and trimeric 
G-proteins (2-5) and protein tyrosine kinases (6-11) play crucial roles in a 
variety of cell signaling events. 
    Protein lipid modifications can be broadly divided into two categories. The 
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first category includes modifications that orient the protein to the outside of the 
cell such as glyocophosphatidylinositol (GPI) anchoring (12-20) and 
cholesteroylation (21-23). GPI moiety is important for the trafficking of proteins 
through the secretory pathway from the endoplasmic reticulum (ER) to the 
Golgi apparatus, and finally to the extracellular face of the plasma membrane. 
The second category of lipidation includes modifications that orient the protein 
to the cytoplasmic side of the plasma membrane, which is what this work will 
be focusing on. These modifications can be further divided into 3 types: 
N-myristoylation (24-28), prenylation (4, 29-35), and palmitoylation (36-44) 
(Table 1.1). N-myristoylation entails formation of an amide bond between the 
N-terminal amino group of a protein and a 14-carbon saturated fatty acid 
(myristate). This is a large category among lipid modifications, as about 5% of 
eukaryotic proteins are N-myristoylated. N-myristoylation occurs on proteins 
with an N-terminal sequence of Met-Gly-. First the N-terminal methionine is 
cleaved, catalyzed by methionine aminopeptidase and then the N-terminal 
glycine reacts with myristoyl-CoA to form an amide linkage, catalyzed by 
N-myristoyltransferase (25). Another type of modification, protein prenylation, 
includes both farnesylation (45-52) and geranylgeranylation (53-55). In this 
case, a cysteine thiol side chain near the C-terminus of a substrate protein 
reacts with a prenyl diphosphate to form a thioester with either a 15-carbon 
(farnesyl) or 20-carbon (geranylgeranyl) isoprenoid group. The enzymes that 
catalyze these modifications, protein farnesyltransferase (FTase) and 
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geranylgeranyltransferase type-I (GGTase-I) recognize canonical protein 
substrates containing a C-terminal ‘CaaX’ box, in which ‘C’ refers to the 
prenylated cysteine residue, while ‘a’ refers to any aliphatic amino acids, and X 
is proposed to be a set of amino acids that determine the type of lipid group 
added to the protein (either farnesyl or geranylgeranyl) (46, 56-58). Once the 
protein is prenylated on the cysteine, the terminal ‘aaX’ sequence can be 
cleaved catalyzed by CaaX protease Rce1, followed by carboxylmethylation of 
the terminal prenyl cysteine catalyzed by protein S-isoprenylcysteine 
O-methyltransferase (ICMT) (59-61). The protein can then be trafficked to the 
Golgi apparatus for additional modifications, processing, and trafficking to the 
plasma membrane. Protein geranylgeranyltransferase type-II (GGTase-II) 
prenylates Rab proteins using a similar catalysis mechanism by recognizing 
the cysteines at or near their C-terminus (55). Lastly, palmitoylation involves 
the formation of a thioester bond between a cysteine thiol side chain and a 
saturated 16-carbon fatty acid (36-44). The major unique feature of this 
modification is that it is readily reversible due to the lability of the thioester 
bond. Therefore rapid palmitoylation and depalmitoylation allow modified 
proteins to be readily shuttled between the plasma membrane and the Golgi 
complex to regulate many cellular functions (62-68). Palmitoylation is 
catalyzed by protein palmitoyltransferases (PATs). Although many PATs have 
been recently identified using sequence homology, the motifs they recognize in 
the substrate proteins are still poorly defined. A summary of the structures, 
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recognition signals, and the corresponding enzymes that catalyze each lipid 
modification are listed in Table 1.1. Studies conducted over the past decades 
have substantially advanced our understanding of not only the molecular 
mechanisms and the functional consequences of these modifications, but also 
disclosed important implications for biomedical research and drug 
development. This thesis will focus on studying the catalytic mechanism and 
molecular recognition of the enzymes responsible for catalyzing two of the 
most important lipidation reactions, palmitoylation and farnesylation. 
 
Table 1.1: Structures, signals, and corresponding enzymes of three types 
of lipid modifications. The lipid portion of each modification in the structures 
is highlighted in red. The recognizing signals for both prenylation and 
N-myristoylation have been well identified, while there has not been a 
consensus signal for palmitoylation. 
Biological Significance of Protein Palmitoylation 
As described earlier, palmitoylation is an important reversible lipid 
modification (62, 63, 65-68). However, palmitoylation functions in the cell are 
more than just a lipid anchor. The reversibility of palmitoylation differentiates it 
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from the other two types of lipid modifications, and allows proteins to be 
shuttled among cellular compartments. A scheme of this process is shown in 
Figure 1.1, where proteins are continually relocalized in the cell or within 
different regions of the membrane through palmitoylation and depalmitoylation 
(69). Therefore, in addition to enhancing the membrane association of proteins, 
palmitoylation also helps target proteins in neurons, recruit proteins into lipid 
rafts, regulate cell signaling processes, etc. (65-67). Defining the active site 
and catalytic mechanism of palmitoyltransferases responsible for this 
modification represents a key step towards understanding its biological 
significance and developing active site-directed inhibitors. 
 
Figure 1.1: Inter-compartment protein shuttling through 
palmitoylation-depalmitoylation cycles. Palmitoylated proteins (shown as a 
red circle with an attached blue fatty acid chain) is trafficked to the plasma 
membrane though either diffusion or vesicle transport, and is then targeted to 
lipid rafts. Depalmitoylation is catalyzed by putative palmitoyl protein 
thioesterase (PPT, shown as a blue oval), leading to a palmitoylated half-time 
of 20 min to 2 h. The depalmitoylated protein diffuses back to the Golgi 
complex where it can be palmitoylated for another cycle. 
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The major function of palmitoylation is likely to promote protein membrane 
association. Palmitoylation required for membrane localization can be divided 
into 4 types of substrate proteins (70-77), which are shown in Table 1.2. 
Proteins can also be dually lipidated with a palmitoyl group and either a prenyl 
group or a myristoyl group. For example, mammalian Ras proteins are 
farnesylated for interacting with cell membrane but additional interactions are 
needed to enhance membrane localization, which is palmitoylation for H-Ras 
and N-Ras, while K-Ras membrane association is enhanced by the 
electrostatic interaction between its positively charged basic sequence and the 
negatively charged plasma membrane (46, 78-80). The first modification in the 
dually lipid modification model (e.g. prenylation and myristoylation) is proposed 
to provide substrate proteins with a weak membrane interaction, while the 
subsequent palmitoylation generates sufficient hydrophobicity for strong 
membrane affinity (81, 82). However, there are a number of proteins that are 
only modified with a palmitoyl group. A good example is the G-protein α 
subunits, which are palmitoylated to enhance the interaction with Gβγ subunits, 
an essential step in cell signaling cycles (43). Regulators of G-protein signaling 
(RGS) also go through a single palmitoylation mechanism, which regulates 
membrane localization and inactivation of G proteins to turn off the G 
protein-coupled receptor signaling pathways (43, 68, 83). 
Furthermore, numerous neuronal proteins are palmitoylated, including 
synaptic scaffolding proteins, G-protein-coupled receptors (GPCRs) and 
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synaptic vesicle proteins (68). Palmitoylation of these proteins is vital for 
regulating proper neuronal development and function, including neuronal 
differentiation, neurotransmission, and neurotransmitter release (84-86). One 
of the first neuronal proteins that was demonstrated to be palmitoylated is 
rhodopsin, in which two cysteines proximal to the transmembrane domain are 
modified with palmitoyl groups (87). Similarly, many GPCRs are palmitoylated 
on analogous cysteines (85). A second example is the dendritic postsynaptic 
density protein 95 (PSD-95) that requires palmitoylation to enhance clustering 
of AMPA receptors at excitatory synapses; furthermore, palmitate cycling of 
PSD-95 also regulates synaptic plasticity (88-90). Palmitoylation of the SNARE  
 
Table 1.2: Four different types of palmitoylation with correlated substrate 
proteins. Although many proteins have been identified to be palmitoylated, the 
recognition signal in the protein is still poorly defined. Palmitoylation could 
happen alone, with the presence of transmembrane domains, or with the 
combination of other lipid modifications. 
                                                              
1 Palmitoylation sites are identified with a *. 
2 Abbreviations used: TMD = transmembrane domain; GPCR = G protein-coupled receptor; 
GRK = G protein-coupled receptor kinase; RGS = regulator of G protein signaling.  
palmitoylation type substrate proteins 
palmitoylation + prenylation 
  -CXC*aaX1 
Ras proteins, Rho Proteins, Gγ subunits 
palmitoylation + myristoylation
  MGC*-1 
Gα subunits, Src family kinases (Yes, Fyn, 
Lck) 
proximal to TMDs2 
 
GPCRs2, viral-envelope proteins (HIV, 
influenza) 
palmitoylation alone Gα subunits, GRKs2, RGS2, SNAP-25, 
PSD-95 
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protein (soluble N-ethylmaleimide-sensitive fusion protein-attachment protein 
receptor) SNAP-25 (25 kDa synaptosome-associated protein) is also important 
for neuronal functions (91). SNAP-25 is located at presynaptic axon terminals, 
and is essential for neurotransmitter release (92). Palmitoylation of SNAP-25 is 
proposed to help regulate aspects of synaptic vesicle fusion, and to target 
synaptic vesicles to the site of transmitter release (93).  
Palmitoylation also functions to target proteins to lipid rafts. Lipid rafts are 
dynamic nanoscale assemblies in the cell membrane that are enriched in 
sphingolipid, cholesterol, and GPI-anchored proteins (94, 95). Studies have 
shown that proteins no longer localize to lipid rafts if palmitoylation is blocked 
by either mutagenesis or inhibition of PATs (28, 96-99). The localization of 
proteins to the lipid rafts is especially important for signaling proteins. The 
best-studied examples are nonreceptor tyrosine kinases (NRTKs) and linker 
for activation of T cells (LAT) which are involved in T cell signaling events 
where mutations of the palmitoylated cysteine residues in these proteins 
disrupt the lipid raft structure, and lead to attenuated T-cell responses 
(100-102). These studies assert the important role that palmitoylation plays in 
localizing proteins to functional membrane subdomains, such as lipid rafts. 
DHHC Protein Family and Palmitoyltransferases (PATs) 
Even though palmitoylation of protein thiols can occur nonenzymatically in 
vitro upon incubation with palmitoyl-CoA within a few hours (103), protein 
palmitoylation in the cell is catalyzed by palmitoylating enzymes, namely, 
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protein palmitoyltransferases (PATs) (78). PATs catalyze the thioesterification 
of cysteines in the substrate protein with a palmitoyl group using palmitoyl-CoA 
as a co-substrate. One of the first identified PATs is the Saccharomyces 
cerevisiae Ras palmitoyltransferase Erf2p/Erf4p (effectors of Ras function) 
(104). As mentioned earlier, Ras proteins are first prenylated on a C-terminal 
cysteine within the CaaX sequence which enhances their localization to the ER 
membrane. Here the Erf2p/Erf4p PAT catalyzes palmitoylation of an upstream 
cysteine which enhances the interaction with the membrane. The two proteins 
in the Erf2p/Erf4p co-purify and are both required for Ras palmitoylation activity. 
Deletions of the ERF2 or ERF4 gene in yeast lead to a decrease in 
palmitoylation and mislocalization of Ras in the cell (105). Phenotypic analysis 
leads to the identification of a second palmitoyltransferase, Akr1p 
(ankyrin-repeat-containing protein), in yeast. This enzyme catalyzes 
palmitoylation of Yck2p (yeast casein kinase 2) both in vivo and in vitro. In the 
AKR1∆ strain, Yck2p localizes diffusely in the cytosol rather than associating 
with the membrane (106).  
Both Erf2p and Akr1p are integral membrane proteins that contain several 
transmembrane domains (TMDs), and share a common DHH/YC-CRD 
(Asp-His-His/Tyr-Cys-cysteine rich domain) positioned between two TMDs (78, 
107). For the majority of PATs the consensus sequence is DHHC, while this 
sequence is DHYC in Akr1p. For both enzymes, mutations in this motif abolish 
the palmitoyltransferase activity, suggesting that this motif is involved in the 
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palmitoylation catalytic mechanism. 
Based on the prediction that the DHHC motif is important for catalytic 
activity of PAT, a search of the yeast genome for the DHHC-containing proteins 
was carried out, leading to the discovery of five other putative PATs, including 
Akr2p, Swf1p, Pfa3p, Pfa4p, and Pfa5p (73, 108-110). All of these proteins 
catalyze palmitoylation reactions with varying substrate recognition. These 
results further confirmed the importance of the DHHC-CRD sequence for PAT 
activity. Similar research has been extended to other organisms as well; there 
are now 23 mammalian DHHC proteins identified and they all possess 
palmitoyltransferase activity. In addition, 15 genes from Caenorhabditis 
elegans and 22 genes from Drosophila melanogaster are also predicted to 
have PAT activity from their conserved DHHC sequence (111). 
Among the 23 mammalian PATs, several are suggested to have 
biomedical relevance as their palmitoylated substrates are involved in the 
pathogenesis of neurological disorders, such as Huntington’s disease 
(DHHC17) (112), schizophrenia (DHHC8) (113), and X-linked mental 
retardation (DHHC9 and DHHC15) (114). One of the most notable example is 
DHHC17, better known as HIP14 (huntingtin interacting protein 14) (112, 115, 
116). HIP14 catalyzes the palmitoylation of several neuronal proteins, 
including huntingtin, PSD-95 (88, 89, 117, 118), and SNAP-25 (91). 
Furthermore, HIP14 activity regulates the subcellular trafficking and function of 
huntingtin, leading to the suggestion that it is involved in the pathogenesis of 
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Huntington’s disease (116). Consistent with this, studies have indicated that 
the N-terminal polyglutamine (polyQ) expansion of the huntingtin protein 
prevents interaction with HIP14, and therefore leads to a decrease in its 
palmitoylation level, which enhances aggregation of the protein (116). Further 
studies on the palmitoylation mechanism of HIP14 as well as other DHHC 
proteins may disclose their exact pathophysiological roles in neurological 
disorders (119).  
Akr1p as a palmitoyltransferase 
Akr1p, the yeast homologue of HIP14, is an 86-kDa integral membrane 
protein with six transmembrane domains. The N-terminal hydrophilic domain 
contains six ankyrin repeat sequences. The topology of Akr1p in the 
membrane indicates that the conserved DHHC-CRD sequence is located on 
the cytosolic side of the membrane between transmembrane domains four and 
five (120). A scheme of the Akr1p domains is shown in Figure 1.2.  
Davis and colleagues have carried out multiple studies demonstrating that 
Akr1p is a palmitoyltransferase that catalyzes the palmitoylation of yeast 
casein kinase (Yck2p) both in vivo and in vitro. In the wild-type (AKR1+) yeast 
cells Yck2p is exclusively trafficked to the cell membrane, whereas in akr1∆ 
cells Yck2p is diffusely localized in the cytoplasm (106). This finding is 
consistent with the role of palmitoylation tethering proteins to the membrane. In 
addition, the C-terminus of Yck2p contains two cysteines that are 
hypothesized as the palmitoylation sites. Consistent with this, mutations of the 
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two C-terminal cysteines (-CC) to serines (-SS), leads to the relocalization of 
Yck2p from the membrane to the cytoplasm, as observed for WT Yck2p in 
akr1∆ cells (106).  
 
Figure 1.2: Schematic representation of the Akr1p sequence. Ankyrin 
repeats are shown in the shaded region; the six transmembrane domains are 
indicated in black and the DHHC domain is highlighted in magenta. 
Furthermore, the DHHC motif of Akr1p is important for catalytic activity as 
observed for Erf2p, mutations in the DHYC motif disable the Akr1p catalytic 
activity; mutation of DH to AA, or C to A eliminates labeling of Yck2p with 
palmitate both in vivo and in vitro (106). 
To search for palmitoylated proteins in yeast, the Davis lab carried out a 
global analysis of yeast membrane proteins using MudPIT (multi-dimensional 
protein identification technology) tandem-MS-based proteomic methodology 
(108). Forty-seven palmitoylated proteins, including Akr1p, were identified by 
MS/MS data. To identify the substrate proteins palmitoylated by each of the 
DHHC-containing palmitoyltransferases, including Akr1p, this proteomic 
method was applied to mutant yeast strains deficient for one of more DHHC 
proteins. To identify the putative substrates of Akr1p, MudPIT analysis was 
carried out on proteins isolated from the akr1∆strain. Akr1p substrates were 
identified with a decreased representation in the MS/MS data. Based on this 
experiment six yeast proteins were identified as potential Akr1p substrates: 
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Yck1p, Yck2p, Akr1p, Ypl199c, Ykl047w, and Meh1p. 
It is worth noting that Akr1p is palmitoylated upon incubation with 
palmitoyl-CoA, which is known as auto-palmitoylation (106). Interestingly, this 
phenomenon has been observed in many other DHHC protein 
palmitoyltransferases as well. The auto-palmitoylation is proposed to be 
enzyme catalyzed since the DHHC sequence is required. Alanine mutations of 
DH or C in the conserved DHYC sequence abolish both the 
auto-palmitoylation and trans-palmitoylation both in vivo and in vitro. The 
cysteine in the DHHC motif has been proposed as the site of 
auto-palmitoylation in PATs; however this has not yet been demonstrated. In 
this work, we use mass spectrometric analysis to demonstrate that the 
cysteine in the DHHC motif is palmitoylated in Akr1p. 
In fact, the auto-palmitoylated enzyme has been hypothesized to be a 
covalent intermediate that occurs during catalysis. In this proposed 
mechanism, a palmitoyl group is first transferred to covalently label an amino 
acid side chain in the PAT, followed by transfer of the palmitoyl group from the 
enzyme to the substrate protein in a second step. Kinetic measurements of the 
Erf2p/Erf4p PAT are consistent with the formation of an intermediate, providing 
support for this mechanism (121).  
Methods used for studying PATs 
Palmitoyltransferases are integral membrane proteins that contain several 
transmembrane domains. Therefore these proteins are difficult to overexpress 
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and purify in large quantities which presents a big challenge to the 
characterization of PATs. In this section, some current methods used to 
express, purify, and characterize of yeast PATs will be presented. 
Expression and purification of yeast PATs 
The largest quantities of active yeast PATs have been obtained using 
galactose inducible yeast expression systems. Active Akr1p has not yet been 
obtained by recombinant expression in E. coli. This is likely due to both the 
difficulty of expression of eukaryotic membrane proteins in bacteria and the 
lack of necessary posttranslational modifications.  
Deschenes and colleagues have optimized the expression of yeast PATs, 
including Erf2p, Akr1p, Pfa3p, Pfa4p, and Pfa5p (122). The FLAG-tagged 
version of these protein genes encoded on a yeast plasmid were transformed 
into yeast strain YPH499, and the cells were grown on selective media. The 
culture was then induced for 16 h by adding galactose at the OD600 of 0.4-0.6. 
The cells were harvested by centrifugation at 1000 × g and lysed by vigorous 
vortexing with glass beads. The unbroken cells were removed by gentle 
centrifugation and the membrane fractions were collected using 
ultracentifugation at 200,000 × g. Membrane-based PAT assays were also 
performed with the diluted membrane fractions of each protein. It was shown 
that the membrane fractions containing PATs were sufficient to palmitoylate 
their corresponding protein substrates, suggesting that the PATs expressed 
well using this system. 
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Purification of PATs was developed using Erf2p/Erf4p as an example. The 
membrane fractions were first solubilized by adding 0.75% (w/v) detergent. A 
few different detergents were tried including dodecylmaltoside (DDM), 
deoxycholic acid (DCA), Trition X-100, octylglucoside, and CHAPS. DDM 
turned out to be the most effective detergent in solubilizing the PAT Erf2p/Erf4p, 
which was tested by immunoblotting for 6×His-Erf2p and FLAG-Erf4p with 
anti-His and anti-FLAG antibodies. Triton X-100 and DCA also provide good 
results in solubilizing the PAT but are less effective in maintaining the 
palmitoylation activity (122). Following protein solubilization, Erf2p/Erf4p was 
then purified using nickel affinity and anion exchange chromatography, with 
DDM present in all wash buffers and the elution buffer. The purified active 
protein was obtained based on UV280, SDS-PAGE, and PAT activity assay. 
To sum up, the expression of the yeast PATs can be best achieved by 
using the galactose incucible yeast expression system, and to extract the 
maximum amount of PAT from the membrane fraction while maintaining the 
most activity, a suitable detergent needs to be added during purification. 
Palmitoylation assays 
To study catalysis of palmitoylation and obtain a better understanding of 
its biological significance, and therefore assisting the drug discovery in treating 
neurological diseases, a robust palmitoylation assay is required. Several 
palmitoylation assays have been developed and used to study PATs; each 
assay has both advantages and disadvantages (123).  
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The first developed and most frequently used assay is the in vivo 
metabolic labeling of proteins using radiolabeled palmitate, most commonly 
[3H]palmitate (89, 104, 124-126). The radiolabeled palmitate is added to the 
cell culture during growth, where the palmitoyl moiety is incorporated onto 
target proteins. The labeling of proteins is evaluated by fractionation of the 
proteins by SDS-PAGE of the cell lysate followed by exposing the dried gel to 
high-sensitivity films. This method provides an efficient way to identify 
palmitoylated proteins and to assess the palmitoylation level of a certain 
protein in living cells. In a pulse-chase format this assay can also be used to 
measure both the palmitoylation and depalmitoylation rates. Disadvantages of 
this method are: low sensitivity requiring long hours of labeling and exposure 
time for detection of the radioactive signal and difficulty with accurately 
quantifying the result, since the in vivo labeling process is affected by many 
cellular factors. Therefore, this method is useful for the initial identification of 
PATs but is not suitable for further mechanistic characterization of the 
enzymes. 
A similar assay labels palmitoylated proteins with ω-azido-fatty acids. In 
this method synthetic ω-azido-fatty acid is added to the cell culture during 
growth, so the target proteins was labeled with a palmitoyl group containing an 
azido group at the end of the fatty acid chain (127). Following in vivo labeling, 
proteins can be extracted and subjected to click chemistry (127, 128) to label 
the proteins with a detectable chemical probes, such as biotin or a fluorophore, 
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to quantify the palmitoylated proteins. This method is both safer and more 
sensitive than labeling with radiolabeled palmitate; however, it requires 
multiple steps and presents challenges for quantification and measurement of 
the time-dependence of the reactions. 
Another commonly used assay is the in vitro palmitoylation assay, in 
which peptides mimicking the protein palmitoylation motif or whole proteins are 
used as substrates, and PATs catalyze palmitoylation upon addition of 
exogenous palmitoyl-CoA (129). When using peptides as substrates, 
fluorescent labeling enhances the sensitivity of the assay and the 
palmitoylated peptides can be separated from the non-palmitoylated peptides 
by high performance liquid chromatography (HPLC). However, not all PATs 
react readily with peptide substrates. When using whole proteins as substrates, 
the radiolabeled palmitoyl-CoA is used so that palmitoylation is detected by 
autoradiography after separation by SDS-PAGE. This method is more 
quantitative, requires less reaction handling for signal detection, and can be 
used to measure time-dependent reactions. This assay has also been applied 
in a cell-based assay format, in which intact cells are incubated with 
fluorescently-labeled peptides and endogenous palmitoyl-CoA. This assay has 
the advantage of speed and simplicity and can be used to study the 
intracellular trafficking of the palmitoylated peptides. The in vitro palmitoylation 
assay has been widely used to study the catalytic mechanism of PATs.   
In a recent kinetic study of Erf2p/Erf4p, the Ras PAT, Deschenes and 
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colleagues introduced a coupled fluorescence-based assay to indirectly 
monitor the rate of CoASH release from palmitoyl-CoA in the palmitoylation 
reaction (121). A standard curve between NADH production and CoASH 
concentration in control reactions with various CoASH amounts was plotted, 
and the PAT activity was determined based on the standard curve. Based on 
the kinetics data obtained using this assay, they concluded that palmitoylation 
by Erf2p/Erf4p is proceeded by a two-step mechanism: the enzyme is first 
auto-palmitoylated to form a palmitoyl-Erf2p intermediate, followed by the 
transfer of the palmitoyl moiety to the Ras2p substrate. This assay does not 
require using the radioactive material, and can be performed on a 96-well plate 
which makes it potential for high-throughput inhibitor screening. The challenge 
is that it is not as sensitive as the radioactive assay, and therefore needs 
sufficient amount of active enzyme and substrate protein to generate 
detectable signal from CoASH. 
Besides the traditional biochemical assays, mass spectrometry has 
become an important tool for studying the posttranslational modifications of 
proteins, including lipidation (126, 130, 131). In this case, the palmitoylated 
proteins are subjected to protease digestion and the resulting peptides are 
separated by chromatography. By comparing the sample spectrum with the 
control (no modification), the peptides with the palmitoyl group are easily 
identified by matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) based on the 272 Da mass shift for the 
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palmitoyl group (132). This method is not quantitative but is a versatile tool to 
identify palmitoylated proteins. However, this method has some complications. 
For example, the thioester linkage is not stable so that the palmitoyl moiety can 
get lost during sample preparation, especially at high or low pH in the presence 
of exogenous thiols. In addition, peptides containing a hydrophobic fatty acid 
chain, like palmitoyl, have low solubility, can stick to separation columns and 
may have poor ionization efficiency. Based on these difficulties, this method 
was optimized by performing an additional step, called fatty acyl exchange 
chemistry, before mass spectral analysis (108, 133-135). This method has 
three basic steps which replace the labile thioester bond with a more stable 
thioether linkage. The first step involves blocking of all of the unlabeled free 
cysteine thiols by reaction with N-ethylmaleimide (NEM). In the second step, 
the thioester bond with the palmitoyl group is cleaved by the addition of 
hydroxylamine, exposing the palmitoylated cysteines. Last, the exposed 
cysteine thiols are reacted with thiol-specific reagents with detectable function 
groups, such as 1-biotinamido-4-[4’-(maleimidomethyl) cyclohexanecarbox 
-amido] butane (Btn- BMCC) and biotin-HPDP. After these steps, the labeled 
peptide is purified and analyzed by mass spectrometry. This optimized method 
has been successfully used to identify palmitoylated proteins in several 
biological systems. For example, Davis and colleagues have successfully 
identified most of the palmitoylated proteins in yeast (108), and Freeman and 
colleagues identified palmitoylated proteins and their sites of modification in 
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lipid raft-enriched and non-raft membranes of mammalian cells (135). This 
method can generate false positives, due to the non-specific nature of the 
reactions; therefore, careful controls and confirmation of the results using other 
biological tools are essential. Overall, this method has great advantages for 
discovering novel palmitoylated proteins but may not be suitable for detailed 
mechanistic studies of the enzymatic reactions. 
To sum up, there are a number of assays that have been developed to 
study protein palmitoylation, with each having their own advantages and 
disadvantages. Using these assays, many novel palmitoylated proteins have 
been identified, some of which have been further mechanistically 
characterized. However, to obtain an in-depth picture of the palmitoylation 
mechanism, faster, more sensitive, and higher-throughput assays are desired. 
Biological significance of protein prenylation 
Protein prenylation is another important lipid modification that tether 
proteins to membranes (4, 29-35, 136). This modification has been shown to 
be essential for the proper biological function of more than 100 proteins, by 
serving as membrane anchors or acting as sites for protein-protein interactions. 
Protein prenylation was first discovered in 1978, when prenylated peptides 
was isolated from secreted yeast sex hormones as part of a yeast mating 
factor (137). Since then, prenylation has been widely studied to illuminate its 
function, structure, and catalytic mechanism. 
Protein prenylation can be divided into three subfamilies: farnesylation 
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(45-52), geranylgeranylation I (35, 138-142), and geranylgeranylation II (Rab 
geranylgeranylation) (53, 55, 143, 144). Farnesylation involves the addition of 
a 15-carbon farnesyl group from farnesyl diphosphate (FPP) onto the cysteine 
thiol of a protein substrate, and this reaction is catalyzed by protein 
farnesyltransferase (FTase). Geranylgeranylation I, catalyzed by protein 
geranylgeranyltransferase type I (GGTase-I), recruits a 20-carbon 
geranylgeranyl group from geranylgeranyl diphosphate (GGPP) to form a 
thioether bond with a protein substrate. Both FTase and GGTase are αβ 
heterodimers and they share a common 48 kDa α subunit with different β 
subunits (35). Mechanistic studies have shown that they both recognize a 
canonical C-terminal CaaX sequence of the substrate protein, with “C” as the 
cysteine that is modified with the farnesyl / geranylgeranyl group, “a” being an 
aliphatic amino acid, and “X” being a certain set of amino acids that determines 
the substrate specificity of the enzyme recognizing either FPP or GGPP (145). 
Later studies have demonstrated broader substrate recognition (146). 
Geranylgeranyltransferase type II (Rab GGTase), modifies Rab proteins with 
the 20-carbon geranylgeranyl group from GGPP using a similar catalytic 
mechanism. However, rather than the CaaX sequence of the substrate protein, 
it recognizes the whole structure of Rab proteins is recognized (147, 148). 
Therefore, Rab GGTase is usually categorized separately and will not be 
further discussed here. 
Protein prenylation has received great interest ever since its discovery 
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due to the potential significant implications for medical research since it has 
been suggested to be involved in many diseases (48, 50, 149-154). For 
example, a large portion of the characterized prenylated proteins are small 
GTPases that belong to the Ras superfamily, including Ras, Rho, Cdc42, Rac, 
Rap, and Rab proteins (153-155). A prenylation pathway of Ras proteins is 
shown in Figure 1.3, and prenylation is indispensable for them to be properly 
processed and trafficked to the plasma membrane for appropriate functions in 
the cell. Mutations of these proteins occur in 30% of all human cancers (156). 
Farnesyltransferase inhibitors (FTIs) have been characterized and are being 
tested in clinical trials as anticancer drugs (157, 158). In addition to inhibition of 
tumor growth, FTIs have also been implicated for the treatment of a rapid 
aging genetic disease, Hutchinson-Gilford progeria, in animal models, which is 
caused by mutations in protein lamin A (159). Lamin A contains a C-terminal 
CaaX motif which is farnesylated and subsequently the C-terminus is 
proteolyzed to dissociate the protein from the nuclear membrane for proper 
function in the nucleus. The mutated form of lamin A, however, lacks the 
protease site and is therefore not processed appropriately. Hence, the 
farnesylated lamin A accumulates in the nuclear membrane which is very likely 
the cause of the symptom. FTI treatment allows lamin A to localize normally to 
the nucleus and releases many of the disease symptoms in animal models. 
Recently, FTIs with specificity for inhibition of parasitic FTases have shown 
promising results in the treatment of parasitic infections. For example, FTIs 
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Figure 1.3: Prenylation pathway of substrate proteins in vivo. With Ras 
protein as an example, the pathway starts with farnesylation on the C-terminal 
cysteine of the protein (highlighted in red), followed by processing with CaaX 
protease and ICMT, generating a new carboxyl methyl group on the modified 
protein. The protein can then be recognized, and further localized to the 
plasma membrane with the assist of either its polybasic region (K-Ras) or 
upstream palmitoylation occurred in Golgi (H-Ras). 
have been reported to inhibit the growth of the Malaria parasite palsmodium 
falciparum both in vivo and in vitro, and inhibitors of the trypanosome brucei 
FTase also inhibits the Trypanosoma brucei cell growth, suggesting the 
development of novel therapeutics against African Sleeping Sickness 
(160-163). Similar to FTIs, GGTase-I inhibitors (GGTIs) also inhibit tumor 
growth. In addition, they have been shown to promote the activity of statins in 
the cholesterol biosynthesis pathway and therefore benefit cardiovascular 
health (164). GGTase I is also a potential targets for antifungal therapies. 
GGTIs have been reported to have antifungal activity for Candida albicans, 
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which is a causing agent of systemic fungal infections in immunocompromised 
individuals (165-167). Finally, the recent observation of host-catalyzed 
prenylation of proteins from bacterial pathogens, such as Legionella 
pneumophila (168), suggests the possibility that FTIs could serve as 
antibacterial agents as well. 
Structural characterization of prenyltransferases 
FTase and GGTase-I are αβ heterodimers, and they contain a common 48 
kDa α subunit, and a homologous β subunit, which is 46 kDa for FTase and 42 
kDa for GGTase-I (142, 169). Both subunits are composed primarily of α 
helices, and the crescent-shaped α subunit is arranged around the 
barrel-shaped β subunits, with a catalytic zinc ion bound to the β subunit near 
the subunit interface. A picture of the overall structure of FTase complexed with 
a peptide substrate and FPP analogue is shown in Figure 1.4. 
The α subunit of these prenyltransferases is composed of a set of seven 
pairs of α helices that form a superhelix. The N-terminal domain is a 
proline-rich domain that is not essential for either the catalytic activity (170) or 
stabilizing the protein structure (171) and has been suggested to interact with 
other cellular factors for directing enzyme localization. The β subunits are 
composed of 14 (for FTase) or 13 (for GGTase-I) helices with very similar 
structures. It has a barrel shape, with six core α helices forming the bottom of 
the barrel, and the other six antiparallel α helices forming the side of the barrel. 
The β subunit is crucial for the catalytic activity of these enzymes as the active 
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and H321β in GGTase-I. In addition, the zinc ion also coordinates the cysteine 
thiolate of the CaaX sequence in the substrate, but does not affect the affinity 
of the prenyl diphosphate substrate (31, 173). Moreover, the catalytic activity of 
FTase is activated by magnesium (174). The magnesium ion stabilizes both 
the reactive conformation of the bound substrate and the pyrophosphate 
leaving group from FPP. Although GGTase-I shares many similarities with 
FTase in terms of structure and mechanism, a lysine side chain replaces the 
magnesium ion for stabilizing product formation (174, 175). 
Substrate recognition and catalytic mechanism of protein 
prenyltransferase 
It has been widely accepted that FTase and GGTase-I recognize the 
protein substrates based on their C-terminal Ca1a2X motif (176-181). The first 
aliphatic a1 residue has been shown from the structure to be solvent-exposed 
and not interact with the enzyme (172). Consistent with this, reactivity of FTase 
with peptide libraries indicate little selectivity at the a1 position. However, the a2 
side chain of the Ca1a2X motif interacts with the hydrophobic cavity of the β 
subunit barrel. Mechanistic studies using peptides containing the Ca1a2X motif 
with varying a2 residues suggest that this position is important for substrate 
recognition (182). These data demonstrate that both hydrophobicity and side 
chain volume are important determinants of reactivity; in particular the binding 
cavity is optimized to bind a side chain with a volume of ~140 Å3 (i.e. Leu, Ile, 
Val) (182). The last residue in the motif, X, refers to a series of amino acids that 
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determine the substrate specificity of the prenyltransferase. FTase prefers 
methionine, serine, glutamine, and alanine, while GGTase-I prefers leucine, 
phenylalanine, and methionine (183). Although the definition of the above 
CaaX paradigm has been accepted for many years, recent computational 
analysis and biochemical studies have shown that many noncanonical amino 
acids could be accepted at the a1, a2, and X position, suggesting the possibility 
of a large number of additional protein substrates of prenyltransferases (146).  
The reaction mechanism of prenylation has been extensively studied in 
the past few decades. Based on the biochemical, structural, and computational 
studies, a model of the catalytic mechanism has been proposed, as shown in 
Figure 1.5. The substrate binding is functionally ordered with FPP binding prior 
to the peptide substrate (35, 58, 169, 184-187).  Once the two substrates are 
bound to the enzyme, structural and biochemical analysis indicates that the 
bound substrates undergo a conformational change in which the last isoprene 
unit of the isoprenoid moiety rotates to bring the C1 atom of FPP (or GGPP) 
close to the reactive cysteine, to assist in forming the new covalent bond (52). 
The pKa of the cysteine thiol is lowered by the stabilizing effect of coordination 
to the zinc metal ion in the active site. The thiolate functions as a nucleophile to 
attack the alpha carbon of the prenyl diphosphate to form an associative 
transition state with carbocation character. This results in the formation of a 
thioether bond between the peptide and the prenyl group with the release of 
the pyrophosphate. In FTase, the negatively charged diphosphate group is 
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stabilized with magnesium ion, and in GGTase-I the leaving group interacts 
with a conserved lysine residue so magnesium is no longer required (174, 175). 
After the chemical step occurs, the product release step is slow and is the 
rate-limiting step of the overall reaction under saturating substrate conditions 
(188, 189). An additional isoprenoid substrate binding to the enzyme-product 
complex facilitates the dissociation of the product (52, 138). However, under 
the subsaturating substrate conditions, where the FPP/GGPP concentration is 
low, the reaction stops at the E•F-Spep complex (at the end of the black 
portion of scheme 1). Under single turnover conditions ([E] > [FPP]) where 
product dissociation is not observed, the rate-limiting step is either the 
conformational change or the chemical step (182). 
Elucidation of the structure and catalytic and kinetic mechanism of protein 
prenylation have enhanced the rational design of prenylation inhibitors for the 
possible treatment of a number of diseases (48, 149, 190-194). Hundreds of 
compounds have been identified as potential farnesyltransferase inhibitors 
(FTIs) in preclinical studies for use as anticancer, antiparasitic, or antifungal 
agents, and some of these are in phase II or phase III clinical trials (48, 50, 
149-151, 190, 193-195). The current inhibitors fall into three categories: FPP 
analogues; peptide-competitive inhibitors; and bisubstrate mimics (142). The 
peptide-competitive inhibitors can be further divided into peptidomimetics and 
nonpeptide inhibitors (196-198). Peptide-competitive inhibitors are by far the 
most promising and prevalent inhibitors among all three types (142); therefore, 
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understanding the substrate recognition and selectivity of the enzyme as well 
as how this process is regulated will provide important information for the 
development of novel peptide-competitive FTIs. 
 
Figure 1.5: Kinetic mechanism of mammalian FTase. Substrate binding is 
functionally ordered with FPP binding before the peptide. E•FPP•Spep in the 
ternary complex undergoes a conformational change followed by formation of 
the thioether bond. Dissociation of the diphosphate product is rapid while 
dissociation of the farnesylated peptide is slow. This step is activated by 
binding of FPP. 
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CHAPTER II 
CATALYTIC CHARACTERIZATION OF YEAST PALMITOYLTRANSFERASE 
AKR1P USING THE NEWLY IDENTIFIED SUBSTRATE YPL199C 
Introduction 
Palmitoylation (1, 2), prenylation (3-6), and myristoylation (7, 8) represent 
three types of common lipid modifications that occur in the cell. During the past 
decade, the enzymes responsible for prenylation and myristoylation have been 
extensively studied, and the target sequences for these modifications have 
been identified. In recent years, palmitoylation has attracted great attention 
due to the reversibility of the thioester modification (9-16), which could allow 
for regulation of protein membrane localization and other lipid-dependent 
interactions (2, 9, 12, 17-22). However, unlike the other two common lipid 
modifications, both the sites of palmitoylation in substrate proteins and the 
catalytic mechanism of the palmitoyltransferases (PATs) are not well 
understood.  
PATs were first identified in yeast more than a decade ago using a genetic 
screen against palmitoylation-dependent Ras proteins (23); afterwards a 
number of PATs have been identified in both yeast and mammals, with each 
catalyzing the palmitoylation of a different set of substrate proteins (24). Many 
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of these substrate proteins are involved in important biological pathways. For 
example, the PAT complex Erf2p/Erf4p (25-28) catalyzes the palmitoylation of 
Ras proteins to enhance membrane association (29), and the PAT HIP14 (18, 
30-32) modifies many neuronal proteins, including PSD-95, SNAP-25 (31) and 
huntingtin protein (htt) (24). Akr1p, an integral membrane protein which is a 
homologue of HIP14 from yeast, catalyzes the palmitoylation of yeast casein 
kinase 2 (Yck2p) to regulate endocytic trafficking (33-36). Davis and 
colleagues have demonstrated that Yck2p is exclusively localized at the 
plasma membrane in cells expressing Akr1p (AKR1+ cells) while diffusely 
localized in the cytosol in akr1∆ cells. Mutation of the two C-terminal cysteines 
of Yck2p to serine also results in cytosolic localization. These data suggest 
that palmitoylation of Yck2p, catalyzed by Akr1p, enhances membrane 
association (35). 
Even though significant effort has been expended to identify palmitoylated 
proteins, the lack of a consensus motif for palmitoylation has made prediction 
of substrate proteins difficult (37). This difficulty is underscored by the large 
variety of protein contexts observed for palmitoylation.  In contrast, sequence 
alignment of the PATs reveals a conserved DHHC (Asp-His-His-Cys) 
cysteine-rich domain (38), a sequence reminiscent of a zinc finger-like motif. In 
several of the PATs including Akr1p, tyrosine is substituted for the second 
histidine of the DHHC motif  (Figure 2.1) (39). Among the DHHC protein 
family, there are 7 proteins from yeast and 23 proteins from humans that have 
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palmitoylation activity (2). Mutations in the DHHC sequence of Akr1p abolish 
the palmitoylation activity (40), implicating this region as a possible active site 
candidate. However, the in vitro observation of DHHC protein-independent 
palmitoylation activity suggests that this domain may not be essential for 
palmitoylation within the cell (37). Thus, identifying the role, if any, that the 
DHHC motif plays in the palmitoylation reaction is an important topic to 
address to understand in vivo palmitoylation. 
 
Figure 2.1: Sequence alignment of the identified yeast and human PATs. 
All of these proteins belong to the DHHC protein family and have 
palmitoylation activity. The consensus motif at the bottom shows that they all 
contain the DHHC-cysteine rich domain (CRD). In Akr1p DHHC is replaced by 
DHYC. Additionally, several of the conserved cysteines are absent in Akr1p. 
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Akr1p is an 86 kDa yeast integral membrane protein containing 6 
transmembrane domains (TMD) and 6 ankyrin repeat sequences; the DHHC 
motif (DHYC in Akr1p) is located between TMD 4 and 5 (41). Since it is a yeast 
membrane protein, overexpression, purification, and stability of the activity in 
detergents represent significant challenges to mechanistic studies of Akr1p. In 
this chapter I will describe the optimization of Akr1p expression and purification 
methods to obtain ~50 μg Akr1p per liter of yeast culture. In addition, this 
chapter describes preliminary characterization of the catalytic properties and 
analysis of the reactivity of Akr1p with a novel substrate that is better suited for 
mechanistic studies. These developments provide useful tools for studying 
Akr1p, as well as other PATs implicated in disease development, such as 
HIP14. 
Experimental Procedures 
Akr1p expression and purification 
The plasmid encoding the AKR1 gene and the expressing yeast strain 
were obtained from the Davis lab at Wayne State University as generous gifts. 
The C-terminal 3xHA/FLAG/6xHis-tagged Akr1p encoded on pRS316 vector 
was transformed into akr1∆ pep4∆ NDY1547 yeast cells, and Akr1p was 
expressed under the control of the GAL1 promoter. Cells were grown in 
SRC-Ura (synthetic raffinose complete-uracil) medium at 30°C to late 
log-phase with ~2×108 cells/mL, pelleted by centrifugation and resuspended in 
20 mL cold TBS (Tris-Buffered Saline) containing 1 mM Dithiothreitol (DTT) 
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and 2x protease inhibitors (Buffer 1). The suspension was slowly dripped into 
liquid nitrogen to form frozen droplets and lysed by 15 min of grinding with a 
mortar and pestle in the presence of liquid nitrogen. The lysate was thawed on 
ice, and the membrane mixture was solubilized by incubation with 1% Triton 
X-100 using end-over-end mixing for 30 min at 4 °C. The undissolved fraction 
was removed by centrifugation at 20,000 × g for 20 min. The supernatant was 
incubated with 4 mL anti-FLAG M2 mAb-agarose (Sigma-Aldrich) for 2 h at 
4 °C, and washed with buffer containing 50 mM HEPES, 150 mM NaCl, 140 
mM sucrose, 1 mM DTT, 0.5 mg/ml bovine liver lipids (Avanti Polar Lipids), 1% 
Triton X-100, pH 8.0. Akr1p was eluted by addition of buffer containing 0.3% 
Triton X-100 and 300 g/ml FLAG peptide (Sigma-Aldrich) to the wash buffer. 
SYPRO® Ruby protein gel staining 
SYPRO® Ruby protein gel stain was purchased from Molecular Probes. 
After electrophoresis, the SDS-PAGE gel was incubated two times with 100 mL 
of fix solution (50% methanol, 7% acetic acid) on an orbital shaker for 15 min. 
The gel was then placed into 60 mL of SYPRO® Ruby stain with 3 cycles of 
heating in a microwave (30 sec) followed by agitation on a shaker (30 sec, 5 
min, and 23 min). After staining, the gel was transferred to a new container and 
washed in 100 mL of wash solution (10% methanol, 7% acetic acid) for 30 min. 
Finally, the gel was rinsed in ultrapure water and visualized on a Typhoon 9410 
phosphorimager with excitation at 457 nm and emission at 610 nm. 
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In vitro palmitoylation assay 
The in vitro palmitoylation reaction contained 5 µCi of [3H]palmitoyl-CoA 
(PerkinElmer), 10 µM Ypl199c substrate protein, 100 mM MES, pH 6.4, 0.2 
mg/ml bovine liver lipids (Avanti), 1 mM DTT, and Akr1p (~30–40 nM). After 
incubation at 30 °C for various time, the reactions were stopped by the addition 
of 400 µL methanol and 150 µL chloroform, and the proteins were pelleted by 
methanol-chloroform precipitation and subjected to SDS-PAGE. The gel was 
fixed by incubation with 4% isopropanol, 10% acetic acid, 0.2% formaldehyde 
and incubated with 20% 2, 5-diphenyloxazole (PPO) in DMSO and dried with a 
gel-dryer. The gel was then exposed to Kodak high-sensitivity film for 72 h to 
visualize radioactive bands. 
Yck2p and Ypl199c substrate proteins 
The N-terminal 6xHis/FLAG/HA-tagged Yck2p (with a D218A mutation) 
and Ypl199c gene encoded on pET30a expression vector were gifts from the 
Davis lab. Both substrate proteins were overexpressed recombinantly in E. coli 
Rosetta DE3 strain transformed with expression plasmids after induction with 
400 µM Isopropyl β-D-1-thiogalactopyranoside (IPTG) at 15 °C for 8 h. The 
cells were pelleted by centrifugation and resuspended in 20 mM Tris, pH 8.0, 
300 mM NaCl, 10 mM imidazole with protease inhibitors. The cells were lysed 
by sonication on ice and the target proteins were purified using Ni-NTA 
agarose (QIAGEN) affinity chromatography. The proteins were washed and 
eluted from the column in a gradient imidazole format using buffer A (20 mM 
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Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole) and buffer B (20 mM Tris, pH 8.0, 
300 mM NaCl, 500 mM imidazole). The protein fractions were combined, 
concentrated using Amicon Ultra-15 Centrifugal Filter Units (Millipore), and 
buffer-exchanged to 20 mM Tris-HCl, pH 7.7, 150 mM NaCl, 10 mM DTT. 
Dependence of Akr1p activity on chelators or metals 
Stock aqueous solutions of 100 mM 2,6-pyridinedicarboxylic acid (DPA) 
and 100 mM ethylenediaminetetraacetic acid (EDTA) were prepared and base 
was added to neutralize the pH. Stock solutions of 5 mM 
N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) and 100 mM 
1,10-phenanthroline stock solutions were prepared in ethanol. Purified Akr1p 
was incubated with 100 mM MES with 20 mM DPA, 100 μM TPEN, 5 mM 1,10- 
phenanthroline, or each of these plus 5 mM EDTA on ice for 1 h. Then the 
enzyme was diluted into the assay mix and the palmitoylation activity was 
measured. For testing the effect of zinc on catalytic activity, Akr1p was 
incubated with various concentrations of ZnSO4 (100 nM, 1 μM, 10 μM, 100 
μM, 500 μM, 1 mM, 2 mM) for 1 h on ice before assaying activity. 
Mutagenesis 
All Akr1p mutations were introduced into the pRS316 plasmid using 
QuikChange methodology (Stratagene). Following confirmation of the desired 
mutation by sequencing, mutant Akr1p was expressed in yeast and purified 
using the same protocol as the WT enzyme. Mutations of Ypl199c were 
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prepared in pET30a plasmid and the mutant proteins were expressed in E. coli 
and purified similarly as described for the WT protein. 
Results 
 Expression and in vitro purification of Akr1p 
I expressed active Akr1p protein encoded on pRS316 plasmid from 
NDY1547 akr1∆yeast strain, which prevents interference from endogenous 
Akr1p. Additionally, to suppress the deleterious effects of the chromosomal 
Akr1p deletion on growth, the -CCIIS sequence was appended to the 
C-terminal of the chromosomal copy of Yck2 (YCK2(CCIIS)). This is a 
recognition sequence for farnesylation of the cysteine 4 amino acids from the 
C-terminus by FTase followed by palmitoylation of the upstream cysteine 
catalyzed by Erf2p. I first expressed Akr1p under the control of the natural 
Akr1p promoter; however the expression yield was very low. To enhance 
expression, I switched to a new plasmid with Akr1p under control of the GAL1 
promoter. In NDY1547 yeast transformed with this plasmid, the expression 
level of Akr1p increased ~10 fold, which is required for characterization of the 
enzyme mechanism.  
Anti-FLAG affinity purification was performed to purify the FLAG-tagged 
Akr1p. The flow chart describing the procedure is shown in Figure 2.2(a), while 
anti-HA western blot of samples 1–4 is shown in Figure 2.2(b), indicating that 
Akr1p was enriched using this procedure. It is important to note that bovine 
liver lipids play a crucial role in reconstituting the palmitoylation activity of 
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Akr1p, possibly by forming a lipid bilayer membrane structure. We have shown 
that without adding this component, Akr1p is inactive. To sum up, after Akr1p 
overexpression and anti-FLAG affinity purification, 40–50 μg of purified Akr1p 
could be obtained from each liter of yeast culture, as indicated by SYPRO® 
Ruby staining of a SDS-PAGE gel (Figure 2.3). 
 
Figure 2.2: Flow chart of the anti-FLAG affinity purification of Akr1p (a). 
Sample 1 contains the total amount of Akr1p expressed in yeast cells, and 
sample 2 contains Akr1p in the crude cell lysate. Sample 3 contains Akr1p in 
the flow through which fails to bind to the agarose, while sample 4 is the 
amount of Akr1p after purification. Anti-HA western blot of a SDS-PAGE gel 
containing Akr1p samples at each step in the anti-FLAG affinity 
purification process (b). For each sample there are 3 lanes: a. empty vector 
control, b. Akr1p lysed by mortar/pestle grinding with liquid N2, c. Akr1p lysed 
by a coffee grinder.  
Determination of the Akr1p concentration 
Akr1p expresses at a very low level in yeast; therefore it is quite a challenge to 
measure its concentration. UV absorbance or coomassie staining of an SDS 
gel is not sensitive enough to detect the protein signal, and western blotting 
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Figure 2.3: SYPRO® Ruby protein gel stain for the determination of the 
Akr1p concentration (a). Different amount of ultrapure BSA and anti-FLAG 
affinity purified Akr1p and GAL1-Akr1p were loaded onto the SDS-PAGE 
protein gel. The gel was then stained using the Ruby staining protocol and 
subjected to Typhoon 9410 phosphorimager analysis with excitation at 457 nm 
and emission at 610 nm. Standard curve of the intensity of the BSA bands 
(b). The protein band intensities were determined using the ImageQuant 
software and the intensities were plotted versus the amount of BSA. The 
amount of purified Akr1p and GAL1-Akr1p were then calculated based on the 
standard curve. 
does not measure the protein concentration with sufficient accuracy or provide 
information about enzyme purity. Herein, I developed a method using the very 
sensitive SYPRO® Ruby protein gel stain to estimate the amount of purified 
Akr1p. Ruby stain has a sensitivity in the 1 ng protein range (42), which is even 
more sensitive than traditional silver stain. To quantify the Akr1p concentration, 
BSA was used as a protein standard, with 5-80 ng loaded lanes on the protein 
gel along with the Akr1p samples (Figure 2.3(a)). The gel was fixed and 
incubated with the Ruby stain, as described in the methods section and 
quantified by phosphorimager analysis of the intensity of each protein band. A 
standard curve was made using the BSA intensities which is reasonably linear 
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in the range of 10-60 ng (Figure 2.3(b)). We assume that BSA and Akr1p are 
stained at about the same level, as Ruby stain provides little protein-to-protein 
variability since it binds to both basic amino acids and the polypeptide 
backbone (43, 44). Figure 2.3(a) shows that switching to the GAL1 
promoter-containing plasmid increases expression level greatly and the 
protein purity is also enhanced. Based on the intensity of the GAL1-Akr1p 
band and the BSA standard curve, 40–50 μg purified Akr1p was obtained per 
liter of yeast culture.    
Identification of a new Akr1p substrate Ypl199c 
The proteomic study carried out by the Davis laboratory (45) identified 
several potential Akr1p substrates, including yeast casein kinase (Yck2p), 
which is a relatively well-studied substrate. However, Yck2p is a casein kinase 
that is heavily phosphorylated at multiple positions by cellular kinases, which 
complicates using this substrate to study palmitoylation. In particular, 
palmitoylation of Yck2p is activated by ATP, suggesting that palmitoylation is 
dependent on phosphorylation (35). Therefore, an alternate substrate could 
significantly simplify mechanistic studies of Akr1p. We therefore compared the 
reactivity of recombinantly expressed Yck2p and Ypl199c, a protein identified 
as an Akr1p substrate by the proteomic analysis (45) with unknown function. 
The protein substrates were incubated with [3H]palmitoyl-CoA and Akr1p 
purified from yeast, precipitated with methanol-chloroform, and fractioned by 
SDS-PAGE. Tritium-labeled proteins were detected by autoradiography. Both 
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Yck2p and Ypl199c are palmitoylated in an Akr1p-dependent manner under 
these conditions; Akr1p catalyzes palmitoylation of Ypl199c to a greater extent 
than Yck2p, while auto-palmitoylation of Akr1p occurs to a similar extent in 
both reactions (Figure 2.4(a)). Using the same assay condition, a 
time-dependent [3H]palmitoyl labeling of Ypl199c catalyzed by Akr1p was 
observed, indicating a single exponential increase of the band intensity (Figure 
2.4(b)). These data demonstrate that palmitoylation of both proteins is readily 
catalyzed by Akr1p. Due to the enhanced reactivity of Ypl199c, we chose to 
use this substrate for further mechanistic studies.  
Ypl199c contains two cysteines at it c-terminus (-FCNCIQSLA), which are 
hypothesized to be its palmitoylation sites. To explore which cysteine(s) is the 
palmitoylation site(s), we made the single and double cysteine mutations to 
serine. As shown in Figure 2.5, C233S showed the same level of 
palmitoylation as WT Ypl199c. Unexpectedly C235S shows a higher level of 
palmitoylation. These data demonstrate that palmitoylation of both cysteines 
can be catalyzed by Akr1p. In addition, the recognition of the palmitoylation 
site is not strict, as long as the cysteine is close to the C-terminus of the protein. 
Other cysteines in Ypl199c are not palmitoylated, as the C233/235S double 
mutant showed no significant labeling.  
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Figure 2.4: Analysis of reactivity of Akr1p with a new protein substrate 
Ypl199c (a). Reactions are done in vitro using the radioactive palmitoylation 
assay. Each 50 μL reaction contains 100 mM MES, pH 6.4, 3.8 μM 
[3H]palmitoyl-CoA (31 Ci/mmol), 10 μM Yck2p or Ypl199c, ~15 nM Akr1p (or 
control) purified from yeast, and 0.2 mg/mL bovine liver lipids. After 1h 
incubation at 30°C, the reactions were stopped by addition of 
methanol-chloroform. The precipitated proteins were fractioned by SDS-PAGE 
and radiolabeled proteins were detected by autoradiography. Palmitoylation 
time course of Ypl199c catalyzed by Akr1p (b). Reactions were carried out 
as decribed in (a) and stopped at varies time points by addition of 
methanol-chloroform. 
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Figure 2.5: Identification of the palmitoylation site(s) in the substrate 
Ypl199c. Ypl199c contains 2 cysteines (C233 and C235) toward its C-terminus 
(-FCNCIQSLA). WT, C233S, C235S, and C233/235S Ypl199c protein were 
recombinantly expressed in E. coli and purified using Ni-NTA column. Each 
protein (10 μM) was added to reactions containing 1.25 μM [3H]palmitoyl-CoA 
and ~60nM Akr1p enzyme purified from yeast. After 1h incubation at 30°C, 
reactions were methanol-chloroform precipitated, run on a SDS-PAGE gel, and 
then subjected to autoradiography to detect the protein labeling level. 
Akr1p activity is dependent on pH but not metal ion 
An important first step in mechanistic studies is identification of conditions 
where the enzyme is maximally active. Therefore, a pH profile of Akr1p 
catalyzed palmitoylation of Ypl199c was carried out at saturating palmitoyl-CoA 
measuring product formation within the linear range of the reaction curve. 
These data indicate that maximal activity occurs between pH 6.0 and 6.5, with 
activity decreasing substantially at both lower and higher pH values (Figure 
2.6). However, the pKa of an unperturbed cysteine is 8.0. It is then reasonable 
to hypothesize that the cysteine thiolate is stabilized by some positively 
charged groups such as a metal ion or some amino acids for efficient catalysis.  
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Figure 2.6: pH profile of Akr1p palmitoylation activity. The 100 mM buffers 
for the pH profile were: acetate (pH 4 and 5); MES (pH 6 and 6.5); bis-Tris 
propane (pH 7-9) and CAPS (pH 10). All assays were done with saturating 
palmitoyl-CoA within the linear range of the reaction curve (1 h reaction time, 
30°C). The reactions were stopped and precipitated by addition of 
methanol-chloroform, run on a SDS-PAGE gel, and then subjected to 
autoradiography to detect the level of palmitoyaltion. 
The sequence alignment of all DHHC proteins shows a conserved 
DHHC-cysteine rich domain (CRD), which has some structural similarity with 
the C2H2 zinc finger domain (46). This leads to the proposal that there might be 
a zinc metal ion bound to Akr1p that is important for function. I therefore tested 
whether Akr1p activity is affected by incubation with metal ions or a variety of 
metal chelators, including EDTA and the more hydrophobic chelators, DPA, 
TPEN, and 1, 10-phenanthroline (structures shown in Figure 2.7). The 
chelators were incubated with the purified enzyme for 1 h on ice before the 
catalytic activity was measured. As shown in Figure 2.7, none of these 
chelators completely eliminated either the auto- or trans-palmitoylation activity 
as proposed for chelators of an essential metal ion (lane 2-7). However, 1, 
10-phenanthroline may partially inhibit trans-palmitoylation (lane 4 and 7) while 
some chelators may enhance activity somewhat. Consistent with this, 
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Figure 2.7: Akr1p activity is not metal-dependent. Purified Akr1p was 
incubated with different chelators (listed in the figure) for 1 h on ice before 
added to initiate the reactions. The reactions were stopped and proteins were 
precipitated by addition of methanol-chloroform. The substrate proteins were 
fractionated on a SDS-PAGE gel, and then subjected to autoradiography to 
detect the protein labeling level. The enzyme incubated with chelators (lane 
2-7) showed similar amount of activities compared to the standard 
non-chelated enzyme (lane 1).  
addition of 2 mM ZnSO4 significantly inhibits the Akr1p activity. To verify that 
Akr1p activity is inhibited rather than activated by the zinc ion, Akr1p activity 
was measured in the presence of zinc concentration varying from 100 nM to 2 
mM. These data demonstrate that Akr1p is not activated by zinc; rather 
inhibition is observed when the total zinc concentration is > 100 μM in the 
pre-incubation enzyme mix in the assay (Figure 2.8). To sum up, there is no 
evidence for a role of a metal in the function of Akr1p.  
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Figure 2.8: Zinc inhibits rather than activates the Akr1p activity. Different 
concentrations of zinc (from 100 nM to 2 mM) were incubated with Akr1p for 1 
h on ice before measuring catalytic activity. The reactions were stopped and 
proteins were precipitated by addition of methanol-chloroform. The substrate 
proteins were fractionated on a SDS-PAGE gel, and then subjected to 
autoradiography to detect the protein labeling level. The palmitoylation activity 
did not change significantly until the zinc concentration reached to 100 μM, 
indicating that zinc is not involved in the catalytic site of Akr1p.  
Mutagenesis studies on the DHYC motif disclose the importance of each 
amino acid 
As a first step in analyzing the catalytic mechanism of Akr1p, we used 
mutagenesis to identify residues essential for efficient catalytic activity. The 
most conserved sequence in the palmitoyltransferases discovered so far, 
including the 23 proteins from human and 7 from yeast, is the DHHC motif 
(DHYC for Akr1p), suggesting that these residues might be important for 
catalysis. Consistent with this, as reported by Roth et. al. (35), mutations in the 
DHYC motif (DH→AA and C→A) abolish catalysis of palmitoylation of Yck2p 
by Akr1p. Furthermore, mutations in this conserved motif in other PATs, 
including C203S in Erf2p (34) and C468S in HIP14 (47), also abolish 
palmitoylation activity. To further elucidate the catalytic importance of each 
residue within this motif, we constructed nine single amino acid mutants: 
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D497A, D497N, H498A, H498N, H498K, Y499H, Y499F, C500S, and C500A. 
None of these mutations significantly affect the yield of Akr1p after purification 
(Figure 2.9). However, all of the mutations at D497, H498 or C500, which are 
strictly conserved across all known DHHC palmitoyltransferases, show at least 
a 100-fold decrease in both palmitoylation of Ypl199c and auto-palmitoylation 
catalyzed by Akr1p (Figure 2.9), demonstrating the catalytic importance of 
these side chains. In contrast, mutation of Y499 to either Phe or His, the amino 
acid observed in other palmitoyltransferases, causes only a 2-3-fold decrease 
in the activity of Akr1p, as indicated by palmitoylation of either Ypl199c and 
Akr1p. 
 
Figure 2.9: D, H, and C residues in the D497H498Y499C500 motif are 
crucial for the Akr1p palmitoylation activity. Reactions are done in vitro 
using the radioactive assay as described in the legend of Figure 2.4. Each 
reaction contains 2.5 μM [3H]palmitoyl-CoA, 10 uM Ypl199c, and ~60 nM WT 
or mutant Akr1p purified from yeast. After 1h incubation at 30°C, reactions 
were methanol-chloroform precipitated, run on a SDS-PAGE gel, and then 
subjected to autoradiography to detect the protein labeling level. An anti-HA 
western blot, detecting HA-tagged Akr1p, is also shown indicating that similar 
amount of WT and mutant Akr1p were obtained after expression and 
purification. 
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Discussion 
Ypl199c as a novel substrate of Akr1p 
Davis and colleague carried out a global analysis of all yeast proteins in 
the membrane fraction to identify palmitoylated proteins using the MudPIT 
(multi-dimensional protein identification technology) tandem-MS-based 
proteomic methodology (45). They successfully detected 47 palmitoylated 
proteins, including 12 of the 15 proteins known at that time plus 35 new ones. 
In addition, to identify the substrate proteins of each DHHC-containing 
palmitoyltransferase, they also applied the proteomic method to mutant yeast 
strains deficient for one DHHC protein (for example, akr1∆strain). As a result, 
the substrate candidates for Akr1p should be underrepresented in the MS/MS 
analysis of palmitoylated proteins in the akr1∆strain. In this way they 
successfully identified 6 yeast proteins as potential Akr1p substrates, whose 
names, functions and localizations are listed in Table 2.1 (45). 
Yck2p is a relatively well-studied substrate protein of Akr1p; however, it is 
a casein kinase, so that it gets heavily phosphorylated in the cell, which 
complicates analysis of palmitoylation. Although we used the D218A mutant 
that decreases the casein kinase activity, multiple bands on SDS-PAGE 
analysis indicate structural heterogeneity. Therefore, the mechanistic studies 
will be simplified by analyzing palmitoylation of an alternate substrate. 
Based on the table above, we cloned the YPL199C and YKL047W gene 
into pET30a vector, and recombinantly expressed them in E. coli. Both 
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Ypl199c and Ykl047w showed Akr1p dependent palmitoylation, while Ypl199c 
had much higher palmitoyl labeling. Moreover, Ykl047w is a membrane protein, 
while Ypl199c is cytosolic, which makes Ypl199c much easier to express and 
purify. I therefore choose Ypl199c for our palmitoylation mechanistic studies. 
Name Function Localization 
Yck1 Type I casein kinase; roles in endocytic 
trafficking and cellular morphogenesis 
Plasma membrane 
Yck2 Type I casein kinase; roles in endocytic 
trafficking and cellular morphogenesis 
Plasma membrane 
Akr1 DHHC-type protein palmitoyltransferase Golgi 
Ypl199c Function unknown Plasma membrane 
Ykl047w Function unknown ER and plasma 
membrane 
Meh1 EGO1; component of the EGO complex; 
regulates microautophagy 
Vacuolar membrane 
 
Table 2.1: Akr1p substrate candidates based on the global analysis of 
protein palmitoylation in yeast. Yck2p has long been identified as the 
substrate of Akr1p. Additional substrates and their cellular locations are 
indicated.  
D, H, and C in the DHYC motif function as a catalytic triad 
The conserved DHHC motif is proposed to constitute a core element 
responsible for the PAT activity. The mutagenesis data (Figure 2.9) confirm 
that the Asp, His, and Cys residues in the DHYC motif are essential for the 
palmitoylation activity of Akr1p. However, how this motif contributes to the 
catalytic mechanism of Akr1p is still unknown. Our functional data demonstrate 
that there is no evidence for involvement of a metal ion in Akr1p function. 
68 
 
Furthermore, it is likely that the cysteine thiolate on the substrate is stabilized 
since this is a better nucleophile than the thiol group. The pH profile suggests 
that the maximal activity is at ~6.5, possibly indicates a decreased thiol 
substrate pKa. Based on these data, the mutagenesis results and literature 
precedents (48), we propose a possible catalytic triad (Figure 2.10) proposing 
potential roles for each amino acid to catalyze palmitoylation. Cysteine 
proteases, like papain, contain a similar catalytic dyad with Asp and His. The 
mutagenesis data are consistent with similar functions of the Cys, His, Asp 
triad in Akr1p. The D497N abolished the activity of Akr1p, implying that either 
the negative charge or hydrogen bond acceptor of aspartate is crucial for the 
catalytic activity, perhaps by enhancing the reactivity of His, as observed in 
papain. Furthermore, neither H498N nor H498K retain the Akr1p palmitoylation 
activity, meaning that the role of histidine is not just to function as a hydrogen 
bond acceptor/donor. Based on the aromatic structure of histidine, we propose 
that it is responsible for facilitating the formation of the thiolate nucleophile on 
the enzyme and the protein substrate. To sum up, D497 and H498 may serve 
to stabilize a nucleophilic thiolate anion for formation of a covalent thiolester 
intermediate, similar to the thiols activation in thiol proteases (48) and 
N-acetyltransferases (49-51). 
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Figure 2.10. The DHYC motif functions as a catalytic triad. A model of a 
catalytic triad formed by D497, H498, and C500 is proposed showing the 
activation of the thiol group of the C500 (the DHYC cysteine), which facilitates 
the formation of a covalent intermediate. 
Auto-palmitoylation has been suggested as a covalent thioester 
intermediate in the catalytic pathway. However it is also possible that 
auto-palmitoylation of a non-active site residue regulates the function of PATs. 
Akr1p mutations affect both auto- and trans-palmitoylation, consistent with a 
catalytic role for this intermediate. A reasonable mechanism showing the 
formation of the covalent enzyme intermediate, based on the mechanism of 
thiol proteases, is proposed in Figure 2.11. In this mechanism a reactive 
cysteine of Akr1p functions as a nucleophile to react with the non-covalently 
bound palmitoyl-CoA to form a new Akr1p-palmitoyl thioester bond with 
formation and dissociation of CoA. With this intermediate, the thiol of the 
protein substrate reacts with the Akr1p thioester to form the palmitoylated 
protein and regenerate Akr1p in a second step. Based on our findings, the X 
group in the scheme stabilizing the cysteine thiolate is composed of the Asp 
and His residues rather than a metal ion.   
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Figure 2.11: Scheme of the proposed Akr1p palmitoylation mechanism 
showing the first auto-palmitoylation step. X indicates one or more groups 
stabilizing the cysteine thiolate, and is proposed to be the Asp and His 
residues. The thiolate then attacks the carbonyl carbon of palmitoyl-CoA as a 
nucleophile and the palmitoyl moiety from palmitoyl-CoA is modified onto the 
stabilized cysteine though the addition-elimination reaction. CoA-SH is then 
released and the structure showing on the right is the auto-palmitoylated Akr1p, 
which is observe in the in vitro palmitoylation reaction.  
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CHAPTER III 
IDENTIFICATION OF PALMITOYLATION SITE(S) IN YEAST 
PALMITOYLTRANSFERASE AKR1P 
Introduction 
DHHC protein family, a group of proteins containing a conserved DHHC 
(Asp-His-His-Cys) motif (1) has attracted much interest in recent years, as they 
have been shown to catalyze protein palmitoylation (2). In addition to 
catalyzing palmitoylation of substrate proteins, DHHC enzymes are also 
auto-palmitoylated (3-8), suggesting that a palmitoylated enzyme serves as a 
covalent intermediate in the reaction pathway. In the recent study of the Ras 
palmitoyltransferase Erf2p/Erf4p, Deschenes and colleagues developed 
assays to simultaneously monitor the kinetics of palmitoylation of both Erf2p 
and Ras2 substrate, and these data suggest that palmitoylation of Erf2p/Erf4p 
occurs by a two-step mechanism: the enzyme is first auto-palmitoylated to 
form a palmitoyl-Erf2p covalent intermediate, followed by the transfer of the 
palmitoyl moiety to the Ras2 substrate (9). The auto-palmitoylated 
intermediate is sensitive to cleavage by hydroxylamine, suggesting a labile 
thioester linkage (3). However, the detailed catalytic mechanism and the role of 
the conserved DHHC motif remain unknown. To investigate the catalytic 
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mechanism of palmitoylation, a critical step is characterization of the 
auto-palmitoylation site(s) in the enzyme to obtain more information about the 
potential intermediate in the palmitoylation reaction. 
Akr1p, the yeast palmitoyltransferase being used in this study, is an 
integral membrane protein with 6 transmembrane domains (TMDs) that 
contains a total of 12 cysteines (4, 10-13), all of which could be potential 
auto-palmitoylation site(s). The DHHC motif of Akr1p (DHYC in this case) is 
located in the cytoplasm between the fourth and fifth TMDs (13). Previously 
Davis and colleagues have demonstrated that Akr1p catalyzes 
auto-palmitoylation, and mutations in the DHYC sequence (DH→AA and C→A) 
eliminate both catalytic activity and auto-palmitoylation (4). This correlation led 
to the proposal that the cysteine in the DHYC sequence is the site of 
auto-palmitoylation but there is no direct evidence for this hypothesis. Herein, 
we combine mutagenesis and acyl-biotinyl exchange (ABE) chemistry coupled 
with mass spectrometry to identify the auto-palmitoylation sites of Akr1p, 
demonstrating that the DHYC cysteine of Akr1p is palmitoylated. 
In the past decade, mass spectrometry has become a versatile tool in 
protein chemistry and has been broadly used for the identification of 
posttranslational modifications (PTMs) (14-18). Electrospray ionization (ESI) 
and matrix-assisted laser desorption ionization (MALDI) sources can generate 
peptide ions that are detected by mass analyzers to determine the m/z value, 
while MS/MS analysis maps the protein sequence to identify the 
78 
 
corresponding PTMs (19-22). Many PTMs, including phosphorylation (23-25), 
glycosylation (26, 27), and acetylation (28, 29), have been successfully 
identified using mass spectrometry. Lipidation has gained increasing 
importance in biomedical research (30-37). Kast and colleagues have 
synthesized a variety of lipidated peptides (myristoylated, farnesylated, and 
palmitoylated), and analyzed them using different mass spectrometric 
methods such as ESI Q-TOF and MALDI-TOF-TOF (38). The results showed 
that for palmitoylation, MALDI generated a neutral loss of the precursor ion of 
CH3(CH2)14COSH (272 Da), while ESI provided a mass shift of 238 Da. These 
unique patterns allow identification of palmitoylation possible using mass 
spectrometric techniques. However, one major challenge of characterizing 
PTM by mass spectrometry is that the fraction of protein containing the 
modification is hard to estimate and may only be a small fraction of the total 
protein (14). This may be more problematic for palmitoylation since this 
modification is readily reversible (36). Therefore, successful identification of 
PTM by mass spectral analysis is usually achieved by including an affinity 
purification step to enrich the modified peptides.  
To enrich palmitoylated peptides, we used the acyl-biotinyl exchange 
(ABE) chemistry to replace the palmitoyl group with a biotin followed by mass 
spectral analysis to identify the auto-palmitoylation sites of Akr1p. The ABE 
chemistry, first introduced by Drisdel and Green, consists of 3 steps (39, 40): 1. 
reduction of cysteine residues followed by reaction of all unmodified cysteines 
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in the protein with N-ethyl maleimide (NEM); 2. cleavage of the S-palmitoyl 
thioester linkage by reaction with hydroxylamine; and 3. labeling of the newly 
exposed cysteine with a biotinylation reagent (such as 
1-biotinamido-4-[4’-(maleimidomethyl)cyclohexanecarbox-amido] butane) for 
enrichment using avidin affinity chromatography. The advantages of this 
method are that the labile thioester linkage is replaced with a more stable 
thioether bond to properly maintain the target modification, and biotinylation 
facilitates the enrichment of the target peptides, which is essential for detection 
by mass spectrometry. This method, coupled with a tandem-MS-based 
proteomic technology, was successfully used by Davis and colleagues to 
identify palmitoylated proteins in yeast (41), and was later modified by 
Freeman and colleagues (42) for both identification of palmitoylated proteins 
and the site of modification in lipid raft-enriched and non-raft membranes on a 
proteomic scale. Here, we use this method to demonstrate that the cysteine in 
the DHYC motif of Akr1p is the site of auto-palmitoylation in vivo, providing 
additional evidence for a covalent thioester intermediate in the catalytic 
mechanism of palmitoyltransferases. 
Experimental Procedures 
General methods 
Mutagenesis of the cysteines in Akr1p, expression and purification of WT 
and mutant Akr1p and protein substrates, and the radioactive palmitoylation 
assay were carried out as described in the methods of Chapter II.  
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Acyl-Biotinyl Exchange (ABE) method (41, 42)  
The C-terminal 3xHA/FLAG/6xHis-tagged Akr1p under the control of the 
GAL1 promoter in plasmid pRS316 was transformed into akr1∆ pep4∆ S. 
cerevisiae. The yeast culture was grown in SRC-Ura medium at 30 °C until 
mid-log phase with an optical density (OD) of 1.0 and induced by addition of 4% 
galactose for 24 h. The cells were pelleted by centrifugation, and ~1×1011 cells 
were resuspended in 20 mL cold lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 5 mM EDTA) containing 2 mM phenylmethylsulfonyl fluoride (PMSF) and 
2x protease inhibitors (5 μg/mL of leupeptin, chymostatin, antipain, and 
pepstatin each). The cells were lysed using a bead beater at a 1:1 lysate/glass 
bead volume ratio with a 15 sec pulse for 10 times with a and 1 min pause in 
between. The cell lysate were first centrifuged at low speed (1000 × g) for 5 
min to remove the cell debris, followed by ultracentrifugation (100,000 × g) for 
45 min at 4 °C to collect the total membrane fraction. Yeast membranes were 
solubilized by incubation with lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 5 mM EDTA) containing 1 mM PMSF, 1x protease inhibitors and 1.7% 
Triton X-100 for 60 min at 4 °C. Following removal of the undissolved 
particulates by centrifugation, protein was precipitated by the 
chloroform-methanol precipitation method (43). The protein pellet was 
redissolved by incubation with SB (50 mM Tris-HCl, 4% SDS, 5 mM EDTA, pH 
7.4) at 37 °C for 10 min, followed by dilution with 3 volumes of lysis buffer (50 
mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA) containing 0.2% Triton 
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X-100, 1 mM PMSF, and 1x protease inhibitors. The protein solution was 
incubated with end-over-end rotation for 30 min with 10 mM 
Tris(2-carboxyethyl) phosphine (TCEP) (Gold Biotechnology) to reduce 
disulfide bonds then incubated with 50 mM N-ethylmaleimide (NEM) (Sigma) 
for 2.5 h at room temperature (RT) to alkylate the thiol moieties. Excess NEM 
was removed by buffer exchange (5x) using Amicon Ultra-15 Centrifugal Filter 
Units (Millipore). This step is critical as the excess NEM will interfere with later 
steps. The protein solution is diluted with SB buffer to a final volume of 2 mL 
and divided into 2 equal samples. Each sample is mixed with 3 mL of freshly 
prepared 1.33 mM N-[6-(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide 
(biotin-HPDP) (Pierce), 0.27% Triton X-100, 33.3% DMF, 1.33 mM PMSF, 
1.33X protease inhibitors, pH 7.4, and either 1 M HA (experimental group; EXP) 
that reacts with thioesters to form free thiols or 50 mM Tris-HCl (control group; 
CON), followed by incubation at RT for 60 min with end-over-end rotation. 
Excess biotin-HPDP was removed by 3 sequential chloroform-methanol 
precipitations. Each protein pellet was dissolved in 0.5 mL TB (2% SDS, 50 
mM Tris-Cl, 5 mM EDTA, pH 7.4), followed by a 20-fold dilution into the lysis 
buffer containing 0.2% Triton X-100, and 680 units of trypsin (Promega) was 
added to digest the protein and incubated at 58 °C for 60 min. Particulates 
were removed by centrifugation at 16,000 × g for 1 min, and the supernatant 
was incubated with 100 μL pre-equilibrated streptavidin agarose beads for 60 
min at RT with end-over-end incubation. After binding, the beads were washed 
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5 times with 50 volumes of equilibrating buffer (50 mM Tris-HCl, 150 mM NaCl, 
5 mM EDTA, 0.2% Triton X-100, 0.1% SDS, pH 7.4), and then washed 2 times 
with 50 volumes of 20% acetonitrile, 10 mM NH4HCO3 to remove the detergent. 
The target peptides were eluted by incubating with 5 volumes of 5 mM TCEP, 
10 mM NH4HCO3, 20% acetonitrile at 37 °C for 30 min to reduce the disulfide 
linkage with the biotin moiety. Samples were centrifuged at 2500 × g for 1 min 
to remove particulates, and the supernatant was dried using a Speed-Vac. The 
peptide samples were stored at -80 °C until mass spectral analysis. 
Mass spectrometry 
Peptide samples were reconstituted in 4:1 (v/v) H2O:acetonitrile. Half of 
the solution was subjected to HPLC-ESI-MS analysis. HPLC was performed 
using an Agilent 1100 series system (Agilent Technologies) on a Phenomenex 
Synergi Hydro reverse phase C18 column (1.0 x 15 mm, Phenomenex). The 
gradient elution increased solvent B from 2% to 70% over 150 min. Solvent A 
was 0.1% formic acid in water and solvent B was acetonitrile with 0.1% formic 
acid. The HPLC eluent was infused online to a 7T Bruker Apex ESI-Q-FT-ICR 
mass spectrometer (Bruker Daltonics). LC-MS data was acquired by Hystar 
and ApexControl software (Bruker Daltonics). Extracted ion chromatograms 
(EICs) were calculated based on the accurate masses of peptides of interest 
and a 20 ppm error window. The elution time of peptides of interest was 
determined by the EICs. The remaining half of the sample was subjected to the 
same HPLC fractionation but the eluent was collected into fractions every 0.5 
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minutes. Fractions containing peptides of interest, based on the elution time, 
were infused into a 7T Bruker SolariX ESI-Q-FT-ICR mass spectrometer 
(Bruker Daltonics). Peptides of interest were fragmented in the gas phase by 
collisional induced dissociation (CID). Each spectrum was signal-averaged for 
approximately 10 minutes. Spectra were manually interpreted and peaks were 
assigned based on a 10 ppm mass error. 
In vivo palmitoyl labeling 
The C-terminal 3xHA/FLAG/6xHis-tagged WT and mutant Akr1p in 
plasmid pRS316 was transformed into akr1∆ pep4∆ S. cerevisiae. The cells 
were grown to an OD of 0.4 in YEP-Raffinose (2%) media. Expressions of WT 
and mutant Akr1p genes under the control of the GAL1 promoter were induced 
by the addition of 2% galactose. After 1 h induction, Akr1p was labeled in vivo 
by addition of 25 μM 17-octadecynoic acid (Cayman Chemicals), an analogue 
of palmitic acid with an alkyne group (44), to the media and incubation for 1 h 
at 30 °C. The cells from a 10 mL culture were harvested by centrifugation at 
2500 x g for 5 min and resuspended in lysis buffer (50 mM Tris-HCl, 150 mM 
NaCl, 5 mM EDTA, pH 7.4) containing 2 mM PMSF and 2x protease inhibitors. 
Cells were lysed by vortexing vigorously with 100 μL glass beads, with 5 x 45 
sec blasts on the vortexer and 1 min rests on ice in between. The lysates were 
collected and solubilized by addition of 0.1% Triton X-100 and incubation at 
4 °C for 30 min. The undissolved fraction was removed by centrifugation, and 
the protein in the supernatant was subjected to methanol-chloroform 
84 
 
precipitation. The protein pellet was then resuspended in 4 % SDS, 50 mM 
Tris-HCl, pH 7.4, 5 mM EDTA, and diluted with 39 volumes of lysis buffer 
containing 0.2 % Triton X-100, 1 mM PMSF and 1x protease inhibitors, 
followed by 30 min end-over-end incubation. The undissolved fraction was 
removed by centrifugation again. The supernatant was incubated with 
anti-FLAG M2 mAb-agarose for 1 h at 4°C, and washed 3 times by lysis buffer 
containing 0.1% SDS and 0.2% Triton. After adding 4% SDS, 50 mM 
triethanolamine (TEA) (Sigma), pH 7.4 to the agarose, Akr1p was eluted with 
incubation at 65 °C for 5 min.  
Click chemistry 
Click chemistry was used to react the alkyne of octadecynoic acid with an 
azide-labeled fluorophore to evaluate whether Akr1p was covalently labeled 
with the palmitate analog. Each 50 μL click chemistry reaction contains 27 μL 
reaction buffer (50 mM TEA, pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 1mM 
PMSF, 1X protease inhibitors), 20 μL of  the FLAG-immunoprecipitated 
protein extract containing Akr1p, 0.5 μL of 10 mM Alexa Fluor 647 azide 
(Invitrogen) in DMSO, 0.5 μl of 10 mM 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) (Sigma) in DMSO, 1 
μl of 50 mM TCEP (Gold Biotechnology), 1 μl of 50 mM CuSO4. The reaction 
mixture was incubated in the dark at RT for 1 h. Then, 100 μL of 50 mM TEA, 
pH 7.4, 150 mM NaCl, 0.5% Triton X-100 was added and the mixture was 
subjected to methanol-chloroform precipitation. The protein pellet was then 
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redissolved in 25 μL buffer (40 mM Tris-HCl, pH 6.8, 8 M urea, 5% SDS, 0.1 
mM EDTA, 1% β-mercaptoethanol (BME)) and incubated at 65 °C for 5 min. 
The solution was then run on a SDS-PAGE gel and the fluorescent protein was 
visualized using a Typhoon-9410 phosporimager. 
Results 
Mutagenesis of cysteine residues in Akr1p reveals possible 
auto-palmitoylation sites 
Akr1p, under both in vivo and in vitro conditions, catalyzes palmitoylation 
of both exogenous proteins and itself (auto-palmitoylation) as previously 
demonstrated (4) and shown in Figure 2.4 in Chapter II. Palmitoylation of 
Akr1p has been proposed as either a catalytic intermediate or as a 
modification to alter membrane localization. To investigate the function and 
sites of the Akr1p auto-palmitoylation, we analyzed potential palmitoylation 
sites by alanine scanning mutagenesis of cysteine residues. There are 12 
cysteine residues in Akr1p: C81, C209, C283, C443, C472, C500, C533, C554, 
C563, C598, C663, and C667. Based on the transmembrane topology data of 
Akr1p (Figure 3.1) (13), we ruled out cysteine side chains with a proposed 
location of buried in the membrane or positioned on the lumen side of Golgi, 
reasoning that only the cysteines with a cytoplasmic orientation would be 
modified with a palmitoyl group in vivo. Thus, eight single mutations (C81A, 
C209A, C283A, C443A, C472A, C500A, C598A, and C663A/C667A) in the 
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Figure 3.1: Schemetic representation of Akr1p membrane topology 
showing the position of all its 12 cysteines. The 6 transmembrane domains 
are indicated in orange, and the DHHC-CRD sequence is labeled in red. 9 of 
the 12 cysteines are located in the cytoplasmic side (labeled in red square) 
and the other 3 cysteines are located either in the transmembrane domain or 
the lumen side (labeled in blue oval) (13). 
Akr1p gene were prepared using site-directed mutagenesis. These mutant 
proteins were expressed in S. cerevisiae and purified as described for WT 
Akr1p (see Chapter II). Similar amounts of protein were obtained for the 
majority of proteins, with the exception of C598A and C663A/C667A double 
mutant where the yield was lower (see western blots shown in Figure 2.9, 3.2, 
and 3.3). The catalytic activity for both auto-palmitoylation and palmitoylation 
of Ypl199c was assayed with [3H]palmitoyl-CoA, using the method described in 
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Chapter II. The C500A mutation in the DHYC motif abolished catalysis of 
palmitoylation of Ypl199c as shown in Figure 2.9 in Chapter II. Alanine 
substitutions for C81, C209, C283, C443, C472, and C598 have no observable 
effect on either catalysis of auto-palmitoylation or palmitoylation of Ypl199c by 
Akr1p under these assay conditions (Figure 3.2). In contrast, the C500A 
mutation and the C663/667A double mutation greatly diminish the 
auto-palmitoylation of the enzyme (Figure 2.9 and 3.2). To further explore 
which cysteine in the C663/C667 double mutation causes this effect, we 
prepared the C663A and C667A single mutations in Akr1p and measured the 
palmitoylation activity. These data clearly shows that C663A has no 
observable effect on palmitoylation but C667A abolishes the 
auto-palmitoylation of Akr1p, indicating that C667 is likely palmitoylated in 
Akr1p (Figure 3.3). These results clearly indicate that both C500 and C667 
affect auto-palmitoylation of Akr1p, and one or both could possibly be the site(s) 
where the palmitoyl thioester forms. 
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Figure 3.2: C663/667A double mutant abolishes the Akr1p 
auto-palmitoylation activity. Reactions are done in vitro using the radioactive 
palmitoylation assay. Each reaction contains 2.5 μM [3H]palmitoyl-CoA, 10 μM 
Ypl199c, and ~60 nM cysteine mutant Akr1p expressed and purified from yeast. 
After a 1 h incubation at 30 °C, reactions were methanol-chloroform 
precipitated, run on a SDS-PAGE gel, and then subjected to autoradiography 
to detect the level of protein labeling. Anti-HA western blotting is also shown to 
indicate that comparable level of HA-tagged Akr1p are obtained for the 
majority of mutants, except for C598A and C663A/C667A where the protein 
level is reduced for this purification. C500A data is cut from the gel in Figure 
2.9 and shown on the right for easy comparison. 
 
Figure 3.3: C667A mutant abolishes the Akr1p auto-palmitoylation 
activity but maintains the trans-palmitoylation activity, while C663A has 
no observable effect on catalysis. Palmitoylation assays were carried out as 
described in the legend of Figure 3.2.  
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The palmitoylation assays demonstrate that the C667A mutation, in 
contrast to the C500A mutation, has little effect on catalysis of palmitoylation of 
Ypl199c, as shown in Figure 3.3. These mutagenesis results indicate that the 
side chain of C500 plays a critical role for catalysis of both palmitoylation of 
substrate proteins and Akr1p, and could potentially be the auto-palmitoylation 
site in Akr1p. On the other hand, the role of C667 is more complicated. 
Although the C667A mutation decreases the level of palmitoylation, as 
indicated in Figure 3.3, this mutation does not significantly alter catalysis of 
palmitoylation of Ypl199c, suggesting that it is not essential for catalytic 
turnover at saturating palmitoyl-CoA. Hence, palmitoylation at this position has 
an alternative function such as acting as a storage site for palmitoyl group or 
an allosteric effector, or regulating the localization of Akr1p. 
Mass spectral analysis demonstrates that the Cys500 in the DHYC motif of 
Akr1p is palmitoylated  
To further examine the roles of C500 and C667 in the catalytic mechanism, 
we carried out the acyl-biotinyl exchange (ABE) chemistry to both replace the 
labile palmitoyl thioester with a more stable disulfide linkage with biotin and to 
enrich the modified peptide followed by mass spectral analysis to identify the 
site of modification. Akr1p has been shown to be auto-palmitoylated both in 
vivo and in vitro. Therefore, we first labeled of Akr1p in vitro. FLAG-tagged 
Akr1p was expressed in yeast and purified using anti-FLAG agarose, followed 
by incubation with palmitoyl-CoA using the assay conditions as described 
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earlier. After the ABE chemistry and proteolysis no peptides were detected by 
mass spectral analysis, possibly due to a low fraction of the Akr1p labeled with 
a palmitoyl group which potentially could reflect a low level of active Akr1p 
reconstituted in the bovine lipids. Therefore, we examined the modification site 
using Akr1p labeled in vivo. Akr1p was expressed in yeast, cells were 
harvested and lysed using a bead beater, and the cell membrane fraction was 
collected by ultracentrifugation and subjected to ABE chemistry. The mixture, 
which contained total yeast membrane proteins, was digested by addition of 
trypsin in the presence of detergent followed by the enrichment of the target 
peptide using streptavidin agarose. The detailed procedure for MS sample 
preparation is shown in Figure 3.4. The key steps in the ABE chemistry are 
labeling all of the unmodified cysteines with NEM, reaction of labile thioester 
bond with hydroxylamine to form a free thiol followed by reaction of this thiol 
with a biotinylation reagent to form a disulfide bond. The biotinylated peptides 
are enriched by binding to streptavidin agarose and eluted from the column 
upon reduction of the disulfide bond. 
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Figure 3.4: Schematic procedure of the acyl-biotinyl exchange (ABE) 
chemistry for the characterization of the Akr1p auto-palmitoylation 
site(s). Top: protection of the thiol groups by reduction with TCEP and 
alkylation with NEM; Bottom left (EXP): replacement of the S-palmitoyl group 
with the biotinyl moiety and enrichment of the S-palmitoylated peptides to 
localize the palmitoylation site(s); Bottom right (CON): control experiment 
where the sample is not treated with hydroxylamine to form cysteine from the 
thioester so the S-palmitoyl group is not replace by a biotin. 
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To identify the modification site(s), the enriched peptide mixture was 
subjected to LC/ESI-FTICR-MS, and the peptide containing C500 
(FDHYCPWIFNDVGLK, m/z = 927 at charge state of two) was detected in the 
sample treated with hydroxylamine (EXP) but not in the control sample (CON) 
(Figure 3.5(a)). In addition, MS/MS analysis of the 927 m/z peak was also 
performed, and the fragmentation pattern of the peptide completely matches 
with the target peptide. As shown in Figure 3.5(b), eleven fragments (y4+, b4+, 
b5+, y7+, y132+, y8+, b8+, y10+, y11+, b11+, and y12+) of the peptide confirm its 
sequence as FDHYCPWIFNDVGLK. These experiments were repeated and 
the C500 peptide was detected with comparable mass spectra. This evidence 
indicates that Akr1p is auto-palmitoylated on C500 in the DHYC motif. 
Additionally, we also looked for the other 10 peptides containing the rest of the 
11 cysteines of Akr1p in the mass spectra (C663 and C667 end up in one 
peptide after the trypsin digestion). None of the m/z values of those peptides 
were detected by mass spectrometry except for the C663/C667 peptide, which 
indicates that those 9 cysteines are not palmitoylated in vivo. For the C663/667 
peptide, we detected an 1165 m/z peak (corresponding to the doubly charged 
peptide with one free cysteine labeled by NEM) in the chromatograms of both 
the EXP sample and the CON sample (Figure 3.6 (a)); however, the MS/MS 
fragmentation did not match the peptide sequence 
TCFGVCYAVTGMDQWLAVIK (Figure 3.6 (b)). As peptides from many 
proteins are enriched by the ABE method when the starting sample is the 
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Figure 3.5: Extracted ion chromatograms of the doubly positively 
charged peptide FDHYCPWIFNDVGLK from HPLC-ESI-FTICR-MS of the 
EXP (red) and CON (blue) samples (a). A signal corresponding to the peptide 
containing the DHYC motif, FDHYCPWIFNDVGLK at m/z=927.4376, is 
detected at 62.9 min of elution for the EXP sample (red), but is not observed at 
the same elution time in the CON sample (blue). The observed signals in the 
CON samples at different elution times are verified as the second or third 
isotopes from other peptides with a similar m/z. MS/MS spectrum of the 
peptide with m/z of 927 collected from the HPLC fractions eluting 
between 62.5 - 63.0 min (b). Eleven fragments (y4+, b4+, b5+, y7+, y132+, y8+, b8+, 
y10+, y11+, b11+, and y12+) of the peptide confirm its sequence as 
FDHYCPWIFNDVGLK.  
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Figure 3.6: Extracted ion chromatograms of the doubly positively 
charged peptide TC(NEM)FGVCYAVTGMDQWLAVIK from the 
HPLC-ESI-FTICR-MS spectra of the EXP (red) and CON (blue) samples (a).  
A signal at 1165.5545 m/z was detected in multiple mass spectra across the 
entire chromatograms of both EXP (red) and CON (blue), as indicated by the 
multiple peaks in (a). However, the isotopic distribution and charge state of the 
peptide of interest were only found in the mass spectrum at 51.3 min. MS/MS 
spectrum of 777 m/z collected by HPLC in fractions between 51.0 and 
51.5 min (b). In this HPLC fraction the doubly-charged form of the peptide of 
interest (1165 m/z) was not detected but 777 m/z, the triply-charged form was 
detected, possibly due to the difference between the two ESI sources used by 
LC-MS and MS/MS. However, none of the expected MS/MS fragments for the 
peptide sequence TC(NEM)FGVCYAVTGMDQWLAVIK were detected, 
suggesting that the signal is from another peptide with the same m/z value.  
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membrane fraction, what we were seeing in the LC-MS spectra is likely 
another peptide which has the same m/z value as our peptide of interest. We 
therefore concluded that although C667 plays an important role in our in vitro 
palmitoylation assay, it does not serve as an auto-palmitoylation site in vivo.  
In summary, these data indicate that C500, not C667, is palmitoylated in 
vivo. This result confirms the catalytic importance of the DHYC motif and 
suggests that auto-palmitoylation could be an intermediate in the catalytic 
cycle. 
To further examine the site of Akr1p auto-palmitoylation, we evaluated in 
vivo palmitoylation of Akr1p using the palmitic acid analog 17-octadecynoic 
acid (17-ODYA). Cultures of yeast transformed with plasmids encoding WT, 
C500A, and C667A Akr1p were induced by addition of 2% galactose and then 
incubated with 17-ODYA which replaces the palmitate modification in vivo (44). 
Click chemistry was then performed on each of the protein extracts to react the 
alkyne of 17-ODYA with Alexa Fluor 647 azide. The reaction mixtures were run 
on a protein gel and scanned for fluorescence using a phosphorimager. As 
shown in the SDS-PAGE gel (Figure 3.7), the in vivo auto-palmitoylation level 
of C500A mutant was greatly decreased compared to that of the WT, indicating 
that C500 is the site of auto-palmitoylation in vivo as well as in vitro. On the 
other hand, the C667A Akr1p mutant showed the same palmitoylation level as 
the WT protein, which suggests that this cysteine does not contribute to the 
auto-palmitoylation of Akr1p in vivo. This result is consistent with our findings 
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from the mass spectral experiment.   
 
Figure 3.7: In vivo labeling of WT and mutant Akr1p with 17-ODYA to 
analyze auto-palmitoylation.3 Yeast cells were incubated with 17-ODYA to 
replace palmitoyl groups with this reagent in vivo. After lysis, the cell lysate 
was subjected to click chemistry to react 17-ODYA with Alexa Fluor 674 azide. 
Each reaction was then run on a SDS-PAGE gel and the fluorescence from 
Alexa Fluor 674 covalently attached to the protein was detected by scanning 
the gel using a phosphorimager. Anti-HA western blotting was also conducted 
to show that WT and mutant Akr1p were expressed at the same level. The 
C500A mutant, but not the C667A mutant, decreases labeling with 17-ODYA, 
indicative of decreased auto-palmitoylation. 
Formation of the intermediate with C667A Akr1p in the presence and absence 
of Ypl199c substrate 
To further examine the role of palmitoylation at C667 of Akr1p, we measured 
auto-palmitoylation of the C667A mutant of Akr1p in the presence and absence 
of the Ypl199c substrate. As previously noted, in the presence of Ypl199c, little 
auto-palmitoylation is observed in this mutant. However, upon the addition of 
substrate Ypl199c, the auto-palmitoylated intermediate of the C667A mutant is 
observed (Figure 3.8). In contrast, for WT Akr1p, the intermediate can be 
observed both in the presence and absence of Ypl199c (see Figure 2.4(a) in 
Chapter II). These results suggest that C667 enhances accumulation of the 
intermediate. When the C667 residue is mutated to alanine, the stabilization 
                                                              
3 Experiment carried out by Roth A. F. 
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effect from C667 no longer exists. When the substrate is absent, the palmitoyl 
moiety has nowhere to be transferred, so the intermediate can still be 
observed. However, when Ypl199c is added to the reaction, without the 
stabilizing effect from C667, the palmitoyl group is transferred from the 
intermediate to the substrate protein, and the intermediate is not sufficiently 
stable to accumulate in the reaction, and therefore the auto-palmitoylation 
species is not observed on our radioactive SDS-PAGE gel. On the other hand, 
the palmitoyl group stays on WT Akr1p due to the stabilizing effect from the 
C667 residue, so the intermediate can be sufficiently accumulated and 
therefore observed. In the in vivo 17-ODYA labeling experiment, the reason 
that we still see the auto-palmitoylation band for C667A is probably because 
the substrate level in the cell is relatively low, so the palmitoyl group stays on 
the enzyme without being transferred to the substrate.  
 
Figure 3.8: Palmitoylation assay of C667A Akr1p with and without 
substrate Ypl199c. Reactions are done in vitro using the radioactive assay. 
Each reaction contains [3H]palmitoyl-CoA, with or without the presence of 
Ypl199c, and C667A Akr1p purified from yeast. After 1h incubation at 30 °C, 
reactions were methanol-chloroform precipitated, run on a SDS-PAGE gel, and 
then subjected to autoradiography to detect the protein labeling level. 
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Discussion 
C500 of the DHYC motif is palmitoylated 
Previous studies have shown that mutation of the DHHC cysteine 
abolishes the palmitoylation activity of PATs (3, 4, 45, 46), leading to the 
hypothesis that this motif is the active site of these enzymes. However, up till 
now there was no clear indication of the role of C500 in catalysis and no direct 
evidence that this cysteine was palmitoylated. The combined mutagenesis and 
mass spectrometry data clearly demonstrate that C500 is covalently modified 
with a palmitoyl group upon auto-palmitoylation of Akr1p. Furthermore, 
mutations that decrease catalytic activity (D, H, C) also eliminate 
auto-palmitoylation, demonstrating that the formation of the intermediate is 
important for catalytic activity. In a recently published paper on the mechanism 
of the Ras palmitoyltransferase Erf2p/Erf4p (9), Deschenes and colleagues 
proposed a two-step catalytic mechanism, where the enzyme is 
auto-palmitoylated in the first step, followed by the transfer of the palmitoyl 
group from the enzyme to the substrate protein. Here we demonstrate that the 
auto-palmitoylated species is a covalent thioester linkage of a palmitoyl group 
with C500 of the DHYC cysteine. These data further validate the catalytic 
importance of a covalent thioester intermediate in the catalytic mechanism of 
Akr1p, and likely all PATs, since the DHH/YC motif is highly conserved.  
To summarize our findings of the role of the DHYC motif using 
mutagenesis and mass spectrometry, we propose a detailed two-step 
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mechanism for Akr1p catalysis (Figure 3.9). In this model, the DHYC cysteine 
thiol is stabilized by the Asp and His residues to lower the pKa of the thiol 
group to form a thiolate at neutral pH, as shown in the catalytic triad model in 
Chapter II. The thiolate functions as a nucleophile to attack the palmitoyl-CoA 
thioester to form a tetrahedral intermediate followed by elimination of –SCoA to 
form a covalent palmitoyl thioester intermediate at C500 of Akr1p. This is 
proposed to be the auto-palmitoylated Akr1p that we have observed both in 
vivo and in vitro. In the second step, the thiolate of the protein substrate 
attacks the carbonyl carbon of the palmitoyl-Akr1p intermediate, and reacts 
 
Figure 3.9: Scheme of the proposed Akr1p palmitoylation mechanism. (1): 
Akr1p with an activated thiol group; (2)-(4): formation of the auto-palmitoylated 
intermediate through attack of the reactive thiolate on the palmitoyl-CoA 
thioester to form a tetrahedral intermediate followed by elimination of CoA to 
form palmitoylated Akr1p intermediate; (4)-(6): the trans-palmitoylation step 
where the thioester of a substrate protein reacts with the palmitoylated Akr1p 
thioester to transfer the palmitoyl moiety to the substrate protein through an 
addition-elimination reaction followed by dissociation of the palmitoylated 
product. 
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with the palmitoyl moiety attached to Akr1p to finally form the product, a 
palmitoyl thioester on the substrate. Many of the details of the proposed 
mechanism still need to be tested. 
The role of C667 
In addition to the examination of the function of the DHYC motif, the 
functional role of C667 is also interesting and valuable. Mutagenesis data 
demonstrate that alanine substitution of C500 and C667 both impaired the 
level of auto-palmitoylation of Akr1p in vitro; however, the C667A mutation had 
no noticeable effect on the trans-palmitoylation activity with the Ypl199c 
substrate. Based on this result, two possible catalytic roles for C667 can be 
proposed: 1. C667 may act as a potential palmitoylation site, same as C500; 2. 
C667 is responsible for stabilizing the auto-palmitoylated intermediate. 
However, since the mass spectral results showed clear identification of 
auto-palmitoylation on C500 while there is no confirmed evidence for the 
formation of a palmitoyl linkage on C667, and in vivo labeling with 17-ODYA 
suggested little labeling of C667, the possibility that C667 is an 
auto-palmitoylation site is unlikely. The disparity between the in vitro and in 
vivo labeling of C667 could also suggest that palmitoylation of C667 is due to 
nonspecific reaction with palmitoyl-CoA. However, the observation of 
auto-palmitoylation in the absence of the protein substrate (Figure 3.8) 
suggests C667 functions to stabilize thioester intermediate at C500 of Akr1p. 
The effect of C667 on the accumulation of C500 is also supported by the 
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spatial orientation of C500 and C667 on the membrane. Although the crystal 
structure of Akr1p is not available, Davis and colleagues have determined its 
membrane topology (Figure 3.1) (13), showing that C500 sits between TM 4 
and 5 in the cytoplasm side, while C667 sits in the same side after TM 6 
toward the C-terminus. Thus the effect of C667 on C500 could be an indirect 
effect, possibly by altering the relative ratio of formation and breakdown of the 
intermediate, or a direct effect of stabilizing the intermediate by forming a 
stabilizing hydrogen bond between the palmitoyl-Akr1p intermediate and C667, 
for example a hydrogen bond with the carbonyl of the thioester.  
In summary, by using mutagenesis and mass spectrometry, we have 
identified the importance of the DHYC motif for the palmitoyltransferase 
activity of Akr1p, and directly showed that the DHYC cysteine is the site for 
formation of the palmitoylation intermediate. Although it has been agreed that 
the conserved DHHC motif of PATs is important for the palmitoylation 
mechanism, no direct evidence has yet been obtained to show the function of 
the DHHC motif. Here, for the first time, we demonstrated that the DHYC motif 
is the reaction site for auto-palmitoylation of Akr1p. As a step further, our 
results allow us to propose a detailed model of the Akr1p catalytic mechanism, 
leading to a better understanding towards the mechanism of all PATs. Taking 
the advantage of the methods described here, the auto-palmitoylation sites of 
other DHHC PATs could also be identified, and therefore the role of this protein 
family in palmitoylation reactions will be disclosed. 
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CHAPTER IV 
CONSERVED AMINO ACIDS IN PROTEIN FARNESYLTRANSFERASE 
MODULATE PEPTIDE SUBSTRATE SELECTIVITY 
Introduction 
Protein prenylation, including both farnesylation and geranylgeranylation, 
is an important posttranslational modification catalyzed by protein 
farnesyltransferase (FTase) or protein geranylgeranyltransferase type I 
(GGTase-I), that enhances membrane localization of the modified proteins in 
the cell (1-3). FTase catalyzes modification of the protein substrate with a 
15-carbon farnesyl group using farnesyl diphosphate (FPP) as a co-substrate, 
while GGTase-I catalyzes addition of a 20-carbon geranylgeranyl group from 
geranylgeranyl diphosphate (GGPP) to the protein substrate (2, 4). Both 
enzymes are αβ heterodimers and they share a common 48 kDa α subunit with 
different β subunits. Both subunits are composed primarily of α helices, and 
the crescent-shaped α subunit is arranged around the barrel-shaped β 
subunits, with a catalytic zinc ion bound to the β subunit near the two-subunit 
interface (5-7).  
More than 100 human proteins have been shown to be farnesylated, 
including G proteins γ subunit (8, 9), Ras (10-13), Rho (14-18), Rac (19), Rap
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(20, 21), and Rab (22, 23) protein families, etc.. Furthermore, farnesylation of 
these proteins is important for the function of cellular pathways implied in a 
variety of diseases, such as cancer and parasitic infections (24-26). Many 
FTase inhibitors (FTIs) have been identified in preclinical studies and several 
are currently being evaluated in clinical studies for treatment of a variety of 
diseases. The FTIs basically fall in three categories: FPP analogues, 
peptide-competitive inhibitors, and bisubstrate mimics (27-32). Among these 
three types, the peptide-competitive inhibitors are the most promising and 
prevalent inhibitors (33-36); therefore, understanding substrate selectivity of 
FTase as well as the structural determinants of this selectivity will provide 
important information for the development of novel peptide-competitive FTIs 
and for the identification of novel FTase protein substrates. 
FTase is proposed to recognize a C-ternimal Ca1a2X sequence in protein 
substrates where “C” represents the cysteine residue that gets farnesylated 
through the thioether bond, while “a” refers to any aliphatic amino acids, and “X” 
is a subset of amino acids, including alanine, serine, glutamine, and 
methionine that contribute to FTase specificity (37-43). However, recent data 
suggest broader substrate recognition (44). Previous data indicate that FTase 
recognizes the a2 residue of the Ca1a2X substrate by a combination of side 
chain hydrophobicity and volume (45).  FTase displays a pyramidal 
dependence on the volume of the a2 residue, with a peak reactivity volume at 
~140 Å3 (when X=S). However, recognition of the a2 residue is dependent on 
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the identity of the X side chain; when X=M there is little dependence on the 
volume of the a2 residue. Nonetheless, analysis of the reactivity of FTase with 
libraries of peptides implicates recognition of the a2 side chain as a major 
determinant of substrate selectivity. The selectivity of the a2 residue is 
presumably determined by the size and properties of the a2 binding pocket. 
The crystal structure of the FTase•peptide complex illustrates that the a2 
binding pocket is formed by the side chains of W102β, W106β, and Y361β, 
together with the third isoprenoid unit of the FPP co-substrate (46). These side 
chains are completely conserved in all FTases, although they are substituted 
with T49β, F53β, and L321β in GGTase (6). 
Previously mutation of Y361β to leucine has been shown to enhance the 
affinity of the GCVLS peptide, a typical substrate for FTase, and this 
substitution also significantly decreases the FTase-catalyzed turnover number, 
reflecting a diminished product association rate (47). Here we demonstrate 
that mutation of either W102β or W106β with smaller or hydrophilic side chains 
has little effect on the steady-state kinetic parameters for farnesylation of the 
GCVa2S peptides. This was an unexpected result since the residues are 
completely conserved and raises the question about the reason for this 
conservation. In this study, we analyze the reactivity of the mutant FTases with 
a library of peptide substrates demonstrating that these two conserved 
tryptophan side chains play important roles in regulating the substrate 
selectivity of FTase. These results provide insight into the structural 
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determinants of FTase required for efficient substrate recognition, and 
therefore shed light onto both potential protein substrates and the future 
design of FTIs.  
Experimental procedures 
Expression and purification of FTase 
Wild-type rat FTase was recombinantly expressed in BL21(DE3) E. coli 
transformed with the pET23aPFT vector (48, 49) after induction by addition of 
isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubation for 16 h at 25 °C. 
Cells were harvested by centrifugation, and lysed using a microfluidizer. FTase 
was purified by sequential DE53 DEAE-cellulose and POROS HQ-20 
anion-exchange columns, with a NaCl gradient. The enzyme concentration 
was determined by active site titration using dansyl-GCVLS (48). FTase was 
then dialyzed into HT buffer (50 mM HEPES, pH 7.8, 2 mM tris(2-carboxyethyl) 
phosphine (TCEP) (Gold Biotechnology)), concentrated to 220 μM, aliquoted, 
and stored at -80 °C.  
Mutagenesis 
Mutations at 102β and 106β in FTase were introduced into the 
pET23aPFT plasmid using QuikChange XL methodology (Stratagene). 
Following confirmation of the desired mutation by sequencing, mutant FTases 
were expressed and purified using the protocol described for WT FTase. 
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Preparation of WT and mutant FTase lysate 
BL21(DE3) E. coli cells containing the pET23aPFT plasmid were grown in 
LB media containing 1 % glucose, 60 μM IPTG, and 100 μg/mL ampicillin for 
22 h at 28 °C. WT and mutant FTase were overexpressed under auto-induction 
conditions. Cell lysates were prepared by mixing 900 μL of cell culture with 100 
μL 10x FastBreakTM (Promega) lysis reagent containing 15 units benzonase, 2 
mg/mL lysozyme, and 0.1 mg/mL phenylmethylsulfonyl fluoride (PMSF), 
followed by 20 min incubation in a shaker at 28 °C. Each enzymatic assay 
contained 2-4 μL of lysate per 100 μL reaction. SDS-PAGE analysis of the 
lysates confirmed that all mutants expressed at a level comparable to the WT 
FTase. 
Peptide substrates 
All peptides are conjugated with dansyl fluorophores at the N-terminus 
with a sequence of GCVa2S, derived from the C-terminal H-Ras sequence 
(CVLS). An upstream glycine is introduced to prevent the inhibitory effect 
caused by an interaction between the N-terminal amine of the peptide and the 
FPP cosubstrate (50). Peptides were purchased from Sigma-Genosys (The 
Woodlands, TX) with >75% purities. The impurities, as shown by mass 
spectrometry, are mainly smaller peptide fragments which are not capable of 
being farnesylated. Peptides were dissolved in absolute ethanol with 10% (v/v) 
DMSO and stored at -80°C. Peptide concentrations were determined from the 
increase in absorbance at 412 nm after reaction of the peptide cysteine thiol 
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with 5,5’-dithiobis(2-nitrobenzoic acid) at pH 7.27, using an extinction 
coefficient of 14150 M-1 cm-1 (51).  
Cell lysate activity assay 
The activity of FTase was measured using clarified cell lysates. Each 
farnesylation reaction contains 0.1-10 μM dansylated peptide, 2-4 μL FTase 
lysate where the FTase concentration is more than 5-fold lower than the 
peptide concentration, 10 μM farnesyl diphosphate (FPP) (Sigma), 50 mM 
HEPPSO, pH 7.8, 5 mM TCEP, and 5 mM MgCl2, in a total volume of 100 μL. 
The assays were carried out at 25 °C in a 96-well plate (Corning). Peptides 
were pre-incubated in the reaction buffer containing TCEP for 15 min to ensure 
that all the peptides were reduced. FPP and FTase were incubated together for 
10 min to form the enzyme-substrate complex. Reactions were initiated by the 
addition of the FTase/FPP mixture to the peptide. Upon farnesylation, the 
increase in the hydrophobicity near the dansyl group enhances the 
fluorescence signal (52, 53). The time-dependent increase in fluorescence 
was measured using a POLARstar Galaxy plate reader (BMG Labtechnologies, 
Durham, NC) with a λex of 340 nm and a λem of 520 nm. 
Steady State kinetic analysis 
The initial velocity and the endpoint fluorescence for FTase-catalyzed 
farnesylation were measured as a function of peptide concentration. A 
conversion factor, which is defined as the ratio between the fluorescence units 
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and the product concentration, was calculated for each peptide by dividing the 
total fluorescence amplitude by the peptide concentration. Using this 
conversion factor, the linear initial velocity was converted from 
∆fluorescence/sec to ∆μM peptide/sec. The Michaelis-Menten equation was fit 
to the dependence of the initial velocity on the peptide concentration to 
calculate values for Vmax, Vmax/KM and KM. Data analysis was conducted using 
Graphpad Prism (Graphpad Software, San Diego, CA).  
Results 
Substrate specificity of W102βA and W106βA mutant FTase 
Preliminary mutagenesis studies (Hougland, unpublished results) 
suggested that substitution of W102β and W106β in FTase with random amino 
acids had little effect on either the recombinant expression levels or reactivity 
with the peptide dansyl-GCVLS. FTase mutants with alterations in both activity 
and substrate specificity were observed in a small library of variants with Trp at 
102β and 106β each substituted with all 20 amino acids. Therefore to further 
explore the functional role of these two completely conserved Trp residues that 
interact with the a2 side chain of the substrate CaaX sequence, we measured 
the reactivity of the W102βA and W106βA mutants with a panel of peptide 
substrates, dansyl-GCVa2S, with varying a2 residues. As shown in Figure 4.1, 
WT FTase selectivity (dashed lines) displays a pyramidal dependence on the 
volume of the side chain at a2; for smaller side chains the volume of kcat/KM 
increases with side chain volume, likely reflecting enhanced Van der Walls 
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contact while the value of kcat/KM decreases with large side chains, presumably 
due to steric hindrance. The peak value for kcat/KM occurs for a side chain 
volume of ~140 Å3, suggesting an ideal size of the a2 binding pocket. Both 
W102βA and W106βA, shown in Figure 4.1(a) and (b) respectively, eliminate 
the FTase substrate selectivity against large side chains at the a2 position 
(a2=M, I, L, F, W), presumably substitution of the large Trp with the small Ala 
residue increases the size of the a2 binding pocket, relieving steric clash with 
the larger a2 side chains. Additionally, the W106βA, but not the W102βA 
 
Figure 4.1: W102βA and W106βA FTase activity with peptide substrates 
dansyl-GCVa2S. 4  All data are obtained using purified enzymes. (a) 
Correlation of log (kcat/KM, mM-1 s-1) for farnesylation catalyzed by W102βA 
FTase with the volume of side chains at the a2 residue in GCVa2S (a2=G, A, S, 
T, V, M, I, L, F, W). The open circles represent the values measured for WT 
FTase and are fit into two groups based on the a2 residue volume (dashed line; 
left: slope = 0.024, R2 = 0.97; right: slope = -0.022, R2 = 0.96). The solid 
squares indicate the reactivity of W102βA mutant and lines are fit to two 
groups of data (solid line; left: slope = 0.025, R2 = 0.99; right: zero slope within 
error). (b) Dependence of log (kcat/KM, mM-1 s-1) on the volume of a2 residues 
catalyzed by W106βA FTase. The WT data (open circles) are identical to those 
described in (a) and the solid squares represent the value of kcat/KM measured 
for farnesylation of GCVa2S peptides catalyzed by W106βA FTase mutant. The 
data are fit based on two groups (solid line; left: slope = 0.014, R2 = 0.98; right: 
zero slope within error). 
                                                              
4 Data obtained by Hougland et al. 
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mutation decreases the activation due to favorable contact with the a2 residue. 
Measuring W102βA and W106βA FTase activity using a cell lysate assay 
To further explore the a2 binding pocket, more W102β and W106β 
mutants were analyzed. To facilitate these experiments, we developed a cell 
lysate-based assay which allows a quantitative evaluation of the catalytic 
activity of the FTase mutants without purification. FTase mutants were 
expressed in E. coli using auto-induction conditions where cells were grown in 
LB media with 1 % glucose and 60 μM IPTG for 22 h at 28 °C. The cells were 
lysed by incubation with the FastBreakTM lysis reagent. SDS-PAGE analysis of 
the lysates was carried out to examine expression levels (Figure 4.2); this gel 
illustrates comparable intensities of protein bands for all of the FTase mutants 
indicating that the protein concentration is comparable for each mutant.  
To validate this assay, we remeasured the reactivity of the WT, W102βA, 
and W106βA FTases with the panel of dansyl-GCVa2S peptides (a2=G, A, T, V, 
L, F, W), and values of Vmax/KM were obtained. As shown in Figure 4.3, using 
this cell lysate-based assay, all WT, W102βA and W106βA FTases showed the 
same trends in substrate specificity as using the purified protein (Figure 4.1). A 
comparison of the value of Vmax/KM measured using cell lysates and kcat/KM 
measured using purified enzymes is shown in Figure 4.1. Vmax/KM values were 
plotted with kcat/KM values, and the data show a linear correlation for both 
W102βA and W106βA FTases with a similar slope of ~10 nM, representing the 
FTase concentration used in the reaction from the cell lysate. These results 
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indicate that the cell lysate-based assay is a feasible tool to quantify the WT 
and mutant FTase activity without purifying a large number of proteins.  
 
Figure 4.2: SDS-PAGE analysis of the lysates of FTase mutants. 6 μL of 
the cell lysate was loaded onto each lane and fractionated by SDS-PAGE. The 
comparable size of protein bands representing α and β subunits of mutant 
FTases indicates that they all expressed to a similar level. W102βA shows 
smaller intensities of the bands possibly due to loading errors, since the rest of 
the proteins in the lane are fainter as well. 
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Figure 4.3: W102βA and W106βA FTase activity with peptide substrates 
dansyl-GCVa2S using the cell lysate-based assay. These data show similar 
trends to those using the purified FTase. (a) Correlation of log (Vmax/KM, s-1) for 
farnesylation catalyzed by W102βA with the volume of the side chains at the a2 
residue in GCVa2S (a2=G, A, T, V, L, F, W). The open circles represent the 
values measured for WT FTase and are fit into two groups based on the a2 
residue volume (dashed line; left: slope = 0.017, R2 = 0.97; right: slope = 
-0.029, R2 = 0.99). The solid squares indicate the reactivity of W102βA mutant 
and lines are fit to two groups of data (solid line; left: slope = 0.019, R2 = 0.88; 
right: zero slope within error). (b) Dependence of log (Vmax/KM, s-1) on the 
volume of a2 residues catalyzed by W106βA FTase. The WT data (open circles) 
are identical to those described in (a) and the solid squares represent the 
value of Vmax/KM measured for farnesylation of GCVa2S peptides catalyzed by 
W106βA FTase. The data are fit based on two groups (solid lines; left: slope = 
0.021, R2 = 1.00; right: zero slope within error). 
 
 
Figure 4.4: Validation of the cell lysate-based assay. (a) Correlation of 
Vmax/KM, measured by the cell lysate-based assay with kcat/KM measured using 
purified W102βA FTase with peptide substrates dansyl-GCVa2S. Data points 
were fit with linear regression. (b) Same as described for (a) except that 
W106βA cell lysate and purified enzyme were used. 
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Substrate selectivity of W102βX and W106βX mutant FTase  
Using this robust cell lysate assay, we measured the reactivity with the 
substrates panel of six additional mutants at both the 102β and 106β positions, 
including W102βS, W102βV, W102βF, W106βS, W106βV, and W106βF. 
These amino acids substitutions provide a range of side chain volumes. For 
each FTase/substrate pair, the value of Vmax/KM was determined using the cell 
lysate assay. The substrate selectivity of these mutants provides insight into 
recognition of the a2 side chain. When Trp is substituted with Phe at 102β 
position (Figure 4.5(a)), the dependence of the reactivity on the a2 side chain 
volume is very similar to the WT pyramidal selectivity profile (Figure 4.3(a)) 
except that the activity peaks at Val rather than Leu. In contrast the W106βF 
mutant has a selectivity profile similar to W102βA FTase with substrate 
peptides containing a2 with small side chains; however discrimination against 
large side chains at a2 is eliminated (Figure 4.5(b)). This significant difference 
in the substrate selectivity pattern of W102βF and W106βF mutants indicates 
that W102β and W106β function differently in determining substrate selectivity 
of FTase, which will be discussed in detail in the discussion section. 
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Figure 4.5: W102βF and W106βF FTase activity with peptide substrates 
dansyl-GCVa2S. All data were obtained using the cell lysate-based assay. (a) 
Correlation of log (Vmax/KM, s-1) for farnesylation catalyzed by W102βF FTase 
with the volume of side chain at the a2 residue in GCVa2S peptides (a2=G, A, T, 
V, L, F, W). The open circles represent the values measured for WT FTase 
same as those in Figure 4.3, and the solid circles indicate the reactivity of 
W102βF mutant and lines are fit into two groups of data (solid line; left: slope = 
0.019, R2 = 0.89; right: slope = -0.026, R2 = 0.99). (b) Dependence of log 
(Vmax/KM, s-1) on the volume of a2 residues catalyzed by W106βF FTase. The 
open circles indicate WT data and the solid circles represent the value of 
Vmax/KM measured for farnesylation of GCVa2S peptides catalyzed by W106βF 
FTase. The data were fit based on two groups (solid lines; left: slope = 0.023, 
R2 = 0.91; right: zero slope within error). 
Additional insights into the determinants of substrate selectivity of FTase are 
revealed by examining the specificity of additional mutants. The Vmax/KM 
values for reaction of each FTase variant at position 102β (W, F, V, S and A) 
are measured and overlayed on a single graph (Figure 4.6 (a)). For these 
variants the catalytic activity for peptides containing small a2 side chains (a2 = 
G, A, T, V) are comparable, suggesting that the increased selectivity as the 
volume of the side chain increases is not due to contact with W102β. However, 
as the size of the side chain at position 102β increases, discrimination against 
substrates with large a2 residues increases; i.e., both WT and W102βF FTases 
120 
 
display significant discrimination against reaction with substrates containing a2 
= Trp and Phe, while less selectivity is observed for the W102βV and W102βS 
FTases and no discrimination is observed for the W102βA mutant. These data 
clearly indicate that W102β side chain contributes significantly to steric 
discrimination without contributing to the Van der Waals contacts to enhance 
reactivity with moderate-sized a2 residues.  
 
Figure 4.6: Overlay of W102βX and W106βX FTase activity with peptide 
substrates dansyl-GCVa2S. All data were obtained using the cell 
lysate-based assay. (a) Correlation of log (Vmax/KM, s-1) for farnesylation 
catalyzed by W102βX (X=W, F, V, S, A) with the volume of the side chains at 
the a2 residue in GCVa2S peptides (a2=G, A, T, V, L, F, W). Each series of data 
are fit into two groups. WT is shown in open circles and fit with dashed line 
(−−); W102βF is shown in filled circles and fit with solid line (—) (as shown in 
Figure 4.5(a)); W102βV is shown in open squares and fit with dotted line (·····) 
(left: slope = 0.022, R2 = 0.98; right: slope = -0.013, R2 = 0.86); W102βS is 
shown in filled triangles and fit with −·− (left: slope = 0.026, R2 = 0.98; right: an 
almost flat slope = -0.005); W102βA is shown in filled squares and fit with −··− 
(as shown in Figure 4.3(a)). (b) Depencence of log (Vmax/KM, s-1) on the 
volume of a2 residues catalyzed by W106βX FTase. Each series of data were 
also fit into two groups as in (a). Open circles and dashed line (−−) still indicate 
WT data; W106βF is shown in filled circles and fit with solid line (—) (as shown 
in Figure 4.5(b)); W106βV is shown in open squares and fit with dotted line 
(·····) (left: slope = 0.028, R2 = 0.96; right: zero slope within error); W106βS is 
shown in filled triangles and fit with −·− (left: slope = 0.023, R2 = 1.00; right: 
zero slope within error); W106βA is shown in filled squares and fit with −··− (as 
shown in Figure 4.3(b)). 
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Residue W106β, on the other hand, presents a very different result. The 
reactivity of WT, W106βF, W106βV, W106βS, and W106βA were all tested with 
the seven peptides and are overlayed on a single plot for comparison (Figure 
4.6(b)). The enhanced reactivity with moderately sized a2 side chains is largely 
unaffected by the mutations, as observed for of W102βX FTase mutants 
(Figure 4.6(a). However, for substrates with larger a2 side chains, all of the 
W106β mutations show a loss of substrate discrimination. This indicates that 
W106β is not the main contributor to the steric discrimination; increasing the 
pocket size at this position (Trp to Phe) is sufficient to eliminate the steric 
hindrance.  
Discussion 
Conserved W102β and W106β regulate the substrate selectivity of FTase 
The crystal structures of –Ca1a2X peptides bound to FTase (46) illustrate 
that the a2 side chain interacts with the indole rings of W102β and W106β as 
well as a phenol ring of Y361β (Figure 4.7). These three amino acids are 
completely conserved in FTases, implying that they play an important role in 
protein function. 
Mutagenesis studies demonstrate that these interactions are important for 
regulating the peptide substrate selectivity of FTase. The kinetic 
measurements of the reactivity of the W102βA and W106βA FTase mutants 
demonstrate that these Trp side chains limit reactivity with –Ca1a2X substrates 
containing large a2 side chains (Figure 4.1 and 4.3). For peptide substrates 
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with an a2 side chain volume ≤ 140 Å3 (Gly (60.1 Å3), Ala (88.6 Å3), Thr (116.1 
Å3) and Val (140 Å3) (54), the W102βA and W106βA FTase mutations have 
little or no effect on the reactivity and substrate selectivity compared to WT 
FTase. However when the a2 residue is large (> 170 Å3, Phe (189.9 Å3) and 
Trp (227.8 Å3)), the mutants at 102β and 106β lose all discrimination against 
the larger side chains. 
Based on the crystal structure shown in Figure 4.7, the a2 binding cavity 
formed by W102β, W106β, and Y361β is estimated to be 180.1 Å3 according 
to the computational result using the POVME algorithm (55). Since this is 
smaller than the side chain volume of Trp or Phe, the discrimination observed 
in WT FTase is likely based on size. This conclusion is consistent with the loss 
of the selectivity against large a2 residues where the size of the pocket is 
increased by substituting the smaller Ala (88.6 Å3) side chain for Trp (227.8 Å3) 
at W102β or W106β. The extra space accommodates a2 side chains and leads 
to comparable reactivity with –CVVS, –CVLS, –CVFS, and –CVWS peptides. 
Previous studies have also demonstrated that Y361β is important for 
selectivity but by a different mechanism. In this case, the Y361βL mutation 
enhances the affinity of the peptide substrate (GCVLS) and leads to a 
substantial decrease in the rate for product dissociation (47). 
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peptides with large a2 groups (Figure 4.6(a)). Thus, the residue at the 102β 
position acts to fine tune the FTase substrate selectivity; the size of the W102β 
side chain alters the volume of the a2 binding pocket, which is reflected in 
enhanced reactivity for peptides with large a2 groups. All mutations, including 
substitution of Trp (227.8 Å3) with Phe (189.9 Å3), completely abolish the 
discrimination of FTase against peptides with large a2 residues. The Trp 
residue at 106β, on the other hand, behaves like a switch for the selectivity of 
FTase: only the bulky tryptophan is large enough to cap the size of the binding 
pocket and thereby allow steric discrimination of peptide substrates. 
The different roles in substrate discrimination can be explained by the 
altered positions of W102β and W106β in the a2 binding pocket. The crystal 
structure (Figure 4.7) demonstrates that the aromatic ring of W102β has a 
facial interaction with the a2 residue, forming one side of the binding pocket. 
Therefore substitution of Trp with other amino acids leads to a limited 
impairment of this interaction. In this way the substrate selectivity becomes 
less sensitive to the size of the a2 side chain as the size of the W102β amino 
acid decreases. However, the aromatic ring of W106β is sandwiched between 
W102β and Y361β, and therefore only interacts with the a2 residue via the 
edge of the ring structure which leads to a defined requirement for the length of 
the side chain at 106β; even a small decrease in length from Trp to Phe 
substitution is sufficient to eliminate substrate selectivity. It is also notable that 
the activity of W106βF mutant is comparable to that of WT with the best 
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substrates and 3-4-fold higher than other mutations at this site. The Phe 
substitution may form an optimal binding pocket for the larger a2 residue.  
The majority of completely conserved residues in proteins are important 
for protein stability, catalytic activity, or high affinity substrate binding. However, 
in FTase, we demonstrated that the two tryptophans are conserved to preserve 
substrate recognition and therefore fine tune the reactivity of multiple protein 
substrates and non-substrates, which is crucial for in vivo functions of FTase. 
In summary, the cell lysate-based assay has proven to be an efficient tool 
to rapidly measure the catalytic activity of FTase mutants. These data have 
delineated the crucial role of the two completely conserved tryptophan 
residues in tuning the substrate recognition of FTase. Future computational 
and structural analysis of the FTase mutants may provide more accurate 
information on the residue interactions within the a2 binding pocket and 
therefore provide additional insight into the determinants of substrate selection. 
These studies will shed light on the design of novel peptidomimetics FTIs and 
prediction of in vivo protein farnesylation substrates. 
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CHAPTER V 
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
Summary and Conclusions 
Catalytic mechanism of protein palmitoyltransferase Akr1p 
Protein palmitoyltransferases (PATs) catalyze S-palmitoylation of 
cysteines in proteins, contributing to membrane targeting, subcellular protein 
trafficking and function. Mutations in PATs are associated with a number of 
neurological diseases and cancer progression (1-6). Even though a number of 
PATs have been discovered (7-14), the understanding of the biological function, 
catalytic mechanism, and regulation is quite limited.  
Akr1p is an 86 kDa yeast protein that has palmitoyltransferase activity (7, 
15). It is an integral membrane protein, which makes it difficult to express and 
purify to a large quantity. This challenge has been partially solved by adding 
the detergent Triton X-100 and bovine liver lipids to solubilize and stabilize the 
membrane protein. Furthermore, expression of Akr1p using the GAL1 
promoter increases the expression level at least 10-fold compared to the 
natural yeast promoter. Through the optimization of an anti-FLAG affinity 
purification method (7), the active Akr1p containing a FLAG-tag was 
successfully purified from yeast. Using the purified enzyme, characterization of 
133 
 
its palmitoyltransferase activity was carried out. Akr1p-dependent 
palmitoylation activity is detected by the covalent modification of a substrate 
protein with a 3H-labeled palmitoyl moiety in the presence of 
[3H]-palmitoyl-CoA. Using this radioactive assay, I demonstrated that, in 
addition to the previously identified Akr1p substrate, yeast casein kinase 2 
(Yck2) (16), Akr1p catalyzes palmitoylation of several other yeast proteins 
including Ypl199c, which is palmitoylated more rapidly by Akr1p. Use of this 
substrate facilitates the kinetic studies of Akr1p. Site-directed mutagenesis of 
the substrate, Ypl119c (Cys to Ser), reveals that two C-terminal cysteines 
(C233 and C235) are the sites of palmitoylation; Ypl119c containing either 
single mutation is palmitoylated by Akr1p but no palmitoylation is observed 
with simultaneous mutations (C233S/C235S). 
Although the structure of Akr1p has not yet been solved, sequence 
homology among PATs suggests that a conserved DHHC (DHYC in Akr1p) 
motif may form a portion of the active site (17, 18). This sequence along with a 
conserved cysteine rich domain (CRD) is proposed to resemble a zinc finger 
domain (19), suggesting the possibility that Akr1p contains a functionally 
important metal binding site. However, the palmitoylation assays carried out 
with different metal chelators and different concentrations of zinc reveal that 
the Akr1p palmitoylation activity is not metal dependent.  
To unravel the catalytic role of the DHYC motif in Akr1p, single mutations 
of each residue in this motif have been prepared, and their contributions to 
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both auto- and trans-palmitoylation activity were quantitatively evaluated. The 
results demonstrate that single mutations of D497, H498 or C500, which are 
strictly conserved across all known DHHC PATs, abolish the palmitoylation 
activity of Akr1p. However, mutation of Y499, which is normally a His in other 
PATs, causes a modest decrease in the activity of Akr1p. To sum up, the 
D497/H498 dyad is essential for catalytic activity. One possible catalytic role 
for these residues is to stabilize the nucleophilic thiolate anion in Akr1p for 
formation of the covalent thioester intermediate, similar to the thiol activation 
mechanism in thiol proteases and N-acetyltransferases (20-22).  
To further explore the important residue(s) responsible for the 
palmitoylation activity of Akr1p and to identify the auto-palmitoylation site, an 
extensive mutagenesis study examining the importance of the majority of the 
cysteine residues of Akr1p has been carried out. These data demonstrate that 
two single alanine mutations, C500A and C667A abolish auto-palmitoylation of 
Akr1p. The C500A mutation also abolishes trans-palmitoylation activity while 
the C667A mutation has little effect on this activity. While either of these 
cysteines could be the site of auto-palmitoylation, palmitoylation at C667 
cannot be an important catalytic intermediate. Furthermore, in the absence of 
the protein substrate, auto-palmitoylation of the C667A mutant is observed. 
This result argue that the cysteine at 667 plays a role in enhancing 
accumulation of the palmitoylated Akr1p, rather than being the site of 
auto-palmitoylation. Overall, the mutagenesis data suggest that C500 in the 
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DHYC motif is the most likely candidate for formation of a thioester 
intermediate in Akr1p.      
To further evaluate the location of the palmitoylated cysteine in Akr1p, 
mass spectrometry has been applied to detect the palmitoylated peptide(s). To 
prevent the loss of the labile palmitoyl group on the protein during sample 
preparation, an acyl-biotinyl exchange (ABE) method was applied to the 
protein before mass spectral analysis (23-25). The palmitoylated peptides 
digested from Akr1p was enriched using the avidin resin and the sequence 
evaluated using ESI-FTICR-MS. The peptide containing C500 has been 
successfully detected, suggesting that C500 is indeed the palmitoylation site of 
Akr1p. However, there is no convincing mass spectral evidence supporting the 
palmitoylation on C667. Taken together these data suggest that the palmitoyl 
thioester at C500 is a reaction intermediate while C667 is not modified but may 
be responsible for stabilizing the auto-palmitoylated intermediate. This is the 
first time that the covalent palmitoylated intermediate has been identified, and 
the importance of the conserved DHHC cysteine has been clearly 
demonstrated. 
These data lead to the proposal of a detailed two-step catalytic 
mechanism of Akr1p (Figure 3.9). First, the thiol group of C500, stabilized by 
the D497/H498 dyad, performs a nucleophilic attack to the palmitoyl-CoA 
thioester. Through an addition-elimination type of reaction, a covalent palmitoyl 
thioester forms with C500 of Akr1p. In the second step, the thiol of the protein 
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substrate reacts with the palmitoyl moiety attached to Akr1p through the same 
type of chemistry proposed in the first step, to form a palmitoyl thioester on the 
substrate. The enzyme is then released for another cycle of catalysis. Overall, 
these conclusions provide significant insight into the catalytic mechanism of 
Akr1p as well as the biological function of palmitoyltransferases. 
Substrate selectivity of protein farnesyltransferase 
Protein farnesylation is an important posttranslational modification in 
which a 15-carbon farnesyl group is modified onto the cysteine of substrate 
proteins resulting in their membrane localization (14, 26-32). Protein 
farnesyltransferase (FTase) catalyzes this process through recognition of a 
specific C-terminal “Ca1a2X” sequence of substrate proteins (33, 34). In 
chapter IV, using peptide substrates containing different a2 residues, it has 
been discovered that completely conserved tryptophan residues in FTase, 
although not essential for maintaining the farnesylation activity, play an 
important role in modulating the substrate selectivity of FTase. A cell 
lysate-based fluorescent assay has been developed for fast analysis of a large 
number of FTase mutants. Detailed mutagenesis studies indicate that W102β 
and W106β both control substrate selectivity and the activity of FTase, and the 
selection patterns are mainly based on the size of the residues at the 102β and 
106β positions. Mutations of the W102β residue diminish the substrate 
selectivity against large amino acids (V, L, F, W) at the peptide a2 position 
based on the size of the substituted amino acid, while mutation of W106β to 
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Phe is sufficient to eliminate substrate selectivity. The complete conservation 
of these two amino acids suggests that maintenance of the exact substrate 
selectivity of FTase is crucial for the in vivo activity. 
Future Directions 
Substrate recognition of Akr1p 
We propose to investigate the use of peptides as substrates for Akr1p to 
develop an assay to facilitate kinetic characterization of the enzyme. 
Myristoylated and farnesylated peptide substrates have previously been used 
to assay palmitoyltransferase activity in membrane fractions. 
Recent studies of substrate specificity in other PATs suggest that regions 
distant from the palmitoylated cysteines are important for conferring specificity 
but are not essential for reactivity (35). Therefore, the model substrates to be 
developed will be useful for mechanistic studies of PATs and for identifying 
molecular recognition determinants near the cysteines. The availability of 
model peptide substrates and enhanced palmitoylation assays will facilitate 
future studies designed to further analyze substrate recognition and to develop 
robust high-throughput screens for inhibitors. 
A dual cysteine motif is conserved near either the N- or C-terminus in all 
five known substrates of Akr1p, with sequence alignments revealing little 
additional residue or motif conservation. This suggests that the dual cysteine 
terminus may play an important role in the molecular recognition of Akr1p. 
Therefore, we propose to design peptide substrates for Akr1p based on the 
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C-terminus of Ypl199c: +H3N-ACNCIQSLA-COO-. The peptides that could be 
tested for activity are listed in Table 5.1. The kinetics of palmitoylation of this 
peptide could be measured by incubation of Akr1p and [3H]palmitoyl-CoA with 
varying concentrations of peptide substrate under conditions identical to those 
used in assays with full-length substrate proteins. Control reactions with no 
added Akr1p or added Akr1p that has been inactivated by previous incubation 
with bromo-palmitate need to be included. Palmitoylation can be monitored 
either by thin layer chromatography or HPLC; addition of the hydrophobic 
palmitoyl group will lead to a change in peptide mobility. If Akr1p does not 
catalyze palmitoylation of the ACNCIQSLA peptide, the reactivity of longer 
peptides derived from the C-terminal sequence of Ypl199c (total length of 10, 
15 and 20 amino acids) and addition of a lipid group to the peptide can be 
Criteria for designing peptide library Strategies for deriving peptides 
from AC(1)NC(2)IQSLA 
Distance between the two cysteine 
residues 
Insert different numbers of alanines 
between C(1) and N, as well as N 
and C(2) 
Residues between the two cysteine 
residues 
Change N to other amino acids 
Distance of the cysteine residue(s) from 
the C-terminus 
Insert different numbers of alanines 
after A 
Residues close to the cysteine residue(s) Change I, Q, S to other amino acids 
Table 5.1: Peptide library designing criteria and sequence examples for 
studying the substrate recognition of Akr1p. 
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explored. The goal in these studies is to find the minimum requirements in a 
peptide to recover significant activity. These results will provide important 
information about molecular recognition in Akr1p, as well as produce reagents 
that will facilitate mechanistic biochemistry on PATs. 
Catalytic mechanism of HIP14 
As mentioned in the introduction chapter, HIP14 (huntingtin interacting 
protein 14), also known as DHHC17, is the mammalian homologue of Akr1p (1, 
2, 32, 36, 37). HIP14 is known to palmitoylate several neuronal proteins 
including the huntingtin protein (htt) (2), PSD-95 (38), SNAP-25 (39), GAD65 
(40), and synaptotagmin I (41-43). Palmitoylation of these proteins is required 
for their subcellular trafficking and function (44-46). One of the most 
noteworthy substrate protein is htt, as the palmitoylation of htt has been 
suggested to be related to the pathogenesis of Huntington’s disease (HD) (37). 
Mutant htt, which contains 6-35CAG repeats encoding the polyQ expansion at 
its N-terminus, presents a reduced level of palmitoylation and shows less 
association with HIP14, and this is proposed to enhance aggregation of the 
protein (36).  Therefore, further studies on the palmitoylation mechanism of 
HIP14 may disclose its exact pathophysiological roles in neurological disorders 
and may provide insights into potential ways of developing medical treatment 
for HD. 
HIP14, like Akr1p, is also an integral membrane protein. The crystal 
structure of HIP14 is not available, but it contains 5 transmembrane domains 
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(TMDs), with the conserved DHHC sequence located between TMD 3 and 4. 
Studies have shown that HIP14∆DHHC, the DHHC-motif deletion version of 
the enzyme, loses its palmitoylation activity. Homologous to Akr1p, HIP14 also 
contains 5 ankyrin repeats in the upstream sequence. A schematic 
representation of the HIP14 sequence is shown in Figure 5.1.  
 
Figure 5.1: Schematic representation of the HIP14 sequence. Great 
similarity could be observed by comparing this scheme to that of Akr1p in 
Figure 1.2. HIP14 contains 5 TMDs (dark blue) with the conserved DHHC 
sequence (pink), and the ankyrin repeats (violet) sit close to the N-terminus.  
To study the palmitoylation mechanism of HIP14, the first step will be to 
express and purify the active enzyme and conduct in vitro palmitoylation 
assays to confirm its activity. Expression clones for HIP14 and its pre-identified 
substrate PSD-95 have been purchased from GeneCopoeia Inc., and both 
clones are inserted in the pReceiver-B13 vector shown in Figure 5.2. PSD-95 
was chosen at the protein substrate because it is one of the best-characterized 
proteins among all of the HIP14 substrates. Both HIP14 and PSD-95 have 
been expressed recombinantly in E. coli Rosetta (DE3) strain. We chose to 
use the bacterial stain because a previous study has reported obtaining small 
amount of active HIP14 expressed in bacteria (1). I demonstrated reasonable 
level of soluble expression of PSD-95 but little expression of HIP14 was 
observed. In the future, the expression conditions and codon usage could be 
optimized as well as switching to expression in other cell lines optimized for 
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expression of mammalian proteins. An initial purification of HIP14 and PSD-95 
has been conducted. As shown in Figure 5.2, both proteins contain His6-Sumo 
tags appended to their N-terminus, allowing for the Ni-affinity purification. The 
expressed proteins were loaded onto and eluted from a Ni-NTA column. 
Following addition of Sumo protease to cleave off the His6-Sumo tag, the 
protein mixture was loaded onto a second Ni-NTA column. The His6-Sumo tag 
should bind to the column while the recombinant protein should elute. However, 
in the initial attempt there was insufficient active Sumo protease, but this could 
be easily solved in the future.  
 
Figure 5.2: pReceiver-B13 vector information for HIP14 and substrate 
PSD-95. Both proteins are expressed under the control of T7 promoter and 
purified using the His6-Sumo tag. 
Following protein purification, in vitro palmitoylation assays could be 
performed with HIP14, PSD-95 and [3H]-palmitoyl-CoA, similar to those 
described with Akr1p. As DHHC motif is essential for HIP14 activity, and HIP14 
has also been reported to be auto-palmitoylated, so it is reasonable to 
hypothesize that the catalytic mechanism of HIP14 is similar to that of Akr1p. If 
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the HIP14-dependent palmitoylation of PSD-95 is successfully observed, the 
mechanism could be examined by mutagenesis study and the ABE-coupled 
mass spectrometry to determine the auto-palmitoylation site(s), as described 
for Akr1p. If HIP14 can be overexpressed in bacteria, this would provide a 
significant advantage for studying palmitoylation since it might be possible to 
obtain large quantities of protein. Therefore many experiments, such as 
developing a better assay for detailed kinetic analysis, which are difficult to 
carry out due to the limited amount of the enzyme, will become feasible. 
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